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ABSTRACT 
The presence of dark melanin (eumelanin) within human epidermis represents 
one of the strongest predictors of skin cancer risk. Topical rescue of eumelanin 
synthesis, previously achieved in “redhaired” Mc1r-deficient mice, demonstrated 
significant protection against UV damage and skin carcinogenesis.  However, 
application of a topical strategy for human skin pigmentation has not been 
achieved, largely due to the greater barrier function of human epidermis. Salt 
Inducible Kinase (SIK) has been demonstrated to regulate MITF, the master 
regulator of pigment gene expression, through its effects on CREB regulated 
transcription coactivator (CRTC) and CRE binding protein (CREB) activity. Here, 
we describe the development of small molecule SIK inhibitors that were 
optimized for human skin penetration, resulting in MITF upregulation and 
induction of melanogenesis.  When topically applied, pigment production was 
	   	  
induced in Mc1r-deficient mice and normal human skin. These findings are the 
first to demonstrate a realistic pathway towards UV-independent topical 
modulation of human skin pigmentation, potentially impacting UV protection and 
skin cancer risk.  
Although MITF normally functions as a regulator of pigmentation, if amplified 
MITF can serve as a melanoma oncogene shown to cooperate with BRAF 
(V600E) to induce tumorigenic transformation of melanocytes . Only 10% of 
melanomas carry an MITF amplification emphasizing the need to identify 
pathways that modulate MITF expression .  Liver kinase B1 (LKB1) regulates 
many cancer-relevant cell phenotypes and is a known SIK inducer . However, the 
interaction of the LKB1-SIK pathway and MITF in melanoma formation is not fully 
understood.  Overall 49% of human melanomas in The Cancer Genome Atlas 
contain aberrations in LKB1, SIK1, SIK2, SIK3, CRTC1, CRTC2, CRTC3, or 
MITF .  Here, we report that the LKB1-SIK axis can negatively regulate MITF 
expression, and our data suggests this is through increasing CRTC2 cytoplasmic 
localization.  Rescue of LKB1 in LKB1-null G361 melanoma cells suppresses cell 
proliferation. MAP kinase pathway activation suppresses MITF, and knockdown 
of all three SIK isoforms rescues MITF expression in NRAS (Q61R) expressing 
melanocytes.  Overall, our findings establish SIK and LKB1 as regulators of the 
CRTC-CREB-MITF pathway and through this regulation, potentially play a critical 
role as tumor suppressors in melanoma oncogenesis. 
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Chapter 1:  Introduction 
Squamous Cell Carcinoma and Basal Cell Carcinoma 
The skin with its versatile biological functions can be divided into three layers: the 
epidermis, dermis, and hypodermis.  The outermost layer of the skin, the 
epidermis, can further be divided into stratum basale, stratum spinosum, stratum 
granulosum, and stratum corneum/horny layer.  The major cell types of the 
epidermis are melanocytes, basal keratinocytes, and squamous keratinocytes 
[7].  These distinct cells types, give rise to the most common forms of skin 
cancers:  basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and 
cutaneous malignant melanoma [8].  BCCs and SCCs together encompass the 
most prevalent cancers in the United States, but currently there is debate on the 
ratio of BCC to SCC, and this may partly be due to the cessation of mandatory 
reporting of these two cancers to national cancer registries and reliance on 
smaller databases for epidemiologic evaluation, but historically BCC is more 
common than SCC [9-12].  While researchers agree the incidence of BCC and 
SCC has increased in the United States over the past two decades, some debate 
remains about the gender specific incidence increase [9, 13, 14].   
Unlike BCC, SCC has a precursor lesion known as actinic keratosis, which 
presents as skin colored, tan, or pink scaly lesions that are usually raised [15] 
[16]. There is no precursor lesion to basal cell carcinoma and depending on type 
can appear pearly, nodular, pigmented, crusty, or ulcerated [17]. 
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Many factors increase the risk of SCC and BCC.  Exposure to ultraviolet radiation 
[18-20], ionizing radiation [21], human papillomavirus [22, 23], arsenic [24], 
psoralen and ultraviolet A therapy [25, 26], use of immunosuppressive agents 
[22, 23, 27-30], and scars after injury to the skin [29] increase the risk of SCC.  
Risk factors for BCC include exposure to ultraviolet radiation [18-20], arsenic [24] 
ionizing radiation [21], and psoralen plus ultraviolet A therapy [31].  A common 
risk factor for both cancers is ultraviolet radiation exposure.  Furthermore, 
alterations in p53 tumor suppressor gene [32-34], RAS oncogene [32, 35], 
p16INK4a tumor suppressor gene [36], p19ARF tumor suppressor gene [37], 
p14ARF tumor suppressor gene [36] have been associated with cutaneous 
squamous cell carcinoma, and mutations p53 [34], p16INK4a [37], and p19ARF 
[37] are UV related mutations. Alterations in p53 tumor suppressor gene [38, 39], 
protein patched homolog (PATCH) [39], and RAS oncogene [35] occur in basal 
cell carcinoma, and p53 and PATCH are primarily UVB signature mutations [39].  
Thus, these UV induced mutations in both cancers reflect the importance of sun 












Over the past decades, the incidence of melanoma has risen in the United States 
[40, 41], Europe [41, 42], and Australia [41].  While the incidence has leveled off 
in the United States and Australia in recent years it is still rising in Europe [41]. A 
higher incidence rate is observed in men than women in the United States [41, 
43].  From 2002-2006 in the United States, the age-adjusted incidence rate for 
cutaneous melanoma for men was 33.2 cases per 100,000 persons (2002-2006) 
and for women was 22.7 cases per 100,000 persons (2002-2006) with an 
incidence men-to-women rate ratio of 1.5. On the other hand, when looking at 
persons 65 years old or older the incidence increases to 130.1 cases per 
100,000 persons (2002-2006) for men and 50.6 cases per 100,000 persons 
(2002-2006) for women with an incidence men-to-women ratio of 2.6:1 [43].  This 
higher incidence in men may be due to disparities in sun safety education, 
attitudes towards tanning, and duration of sun exposure [44].  There is also an 
association with cutaneous melanoma risk and higher socioeconomic status [45, 
46]. 
Mortality rates have also risen in Europe [42], but remain stable in the United 
States [47, 48] and Australia [47].  In the United States, the mortality rates for 
persons under 65 years old was 1.6-1.7 cases per 100,000 persons in 2004 and 
for persons 65 years old and older was 13.8-14.7 cases per 100,000 persons in 
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2004.  Under the age of 65, men have a 2-fold higher mortality rate than women, 
and for persons 65 and older, the mortality rate is 2.7-fold higher in men than 
women [48].  This disparity may be once again explained by differences in 
attitudes, behaviors, and beliefs about sun exposure and sun protection between 
the sexes [44].   
 
Risk Factors 
There are multiple risk factors for developing cutaneous melanomas.  High 
numbers of nondysplastic and dysplastic nevi are risk factors for cutaneous 
melanoma [49-51].  The risk of developing a cutaneous melanoma also 
increases with a family history of melanoma [52].  There are additionally also 
physical characteristics that are associated with a higher risk of developing 
melanoma including having lighter skin tone versus darker skin tone [52], blue 
eye color versus brown/dark eye color [52], red hair color versus dark hair 
color[51, 52], and having many freckles [52].  Furthermore, having actinic 
keratoses, squamous cell carcinomas, and basal cell carcinomas is associated 
with increased risk of melanoma, and increased risk was also associated with 
solar lentigos (sun induced hyperplasia of melanocytes ranging from 5-10 mm), 
elastosis (increased thickened elastic fibers in the dermis), and other indicators 
of skin damage [8, 52].   There is also an increase risk for developing melanoma 
with increasing number of sunburns per year [51, 53] and most significantly 
associated with sunburns occurring during or before adolescence [51, 54]. 




Invasive melanoma can be separated into categories based on clinical and 
histological presentation.  These categories include in order of prevalence:  
superficial spreading melanoma (70%), nodular melanoma (5%), acral 
lentiginous (5-10%), and lentigo maligna melanoma (4-15%) (malignant 
melanoma in situ) [55].  Superficial spreading melanomas are lesions on sun-
exposed areas most commonly found on the back in men and on the backs of 
legs in women.  Nodular melanoma, often ulcerating lesions, has a relative 
gender prevalence that is markedly increased in men and most commonly found 
on the trunk and limbs.  Acral lentiginous melanomas occur on palms, soles, nail 
beds, and other hairless skin and typically effect Asian, Hispanic, and African 
patients [55].  Lentigo maligna melanoma’s, which may progress from lentigo 
maligna, a noninvasive melanoma in situ (although research shows that risk of 
progression is relatively low) usually occurs in sun-damaged areas of the skin 
and can appear benign. [55, 56].   
Physicians use the ABCDs of melanoma, first described in 1985 by Friedman et 
al., to help diagnose early malignant melanoma by physical inspection:  A = 
asymmetry, B = border irregularity, C = color irregularity, D = diameter ≥ 6 mm 
[57], and “E” was added to this diagnostic criteria later for evolution [58]. There 
also exists a 7-point checklist, referred to as the Glasgow checklist, which 
separate features into major features (change in size, irregular shape, irregular 
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color) and minor features (largest diameter ≥ 7 mm, inflammation, oozing, 
change in sensation).  Both diagnostic criteria seem to be sensitive tests for 
melanoma diagnosis [59].  Furthermore, recent studies have shown that 
dermoscopy, application of a magnifying device that utilizes cross-polarized light 
to visualize structures within the epidermis and dermis, is more accurate than 
examination by the naked eye and the commonly used checklists [60].  
 
Driver Mutations 
Melanoma has many driver mutations (Figure 1).  In 2002, BRAF, a member of 
the RAF (rapidly accelerated fibrosarcoma) family, V600E (first reported as 
V599E)  mutation was discovered to be present in 66% of malignant melanoma 
by Davies et al.  [61-63].  Other major oncogenic mutations found in melanoma 
include NRAS activation (15%-30% mutated), microphthalmia-associated 
transcription factor (MITF) amplifications (10-15% amplified), the cytokine 
receptor KIT activation (20%-25% mutated), cell cycle regulator cell cyclin D1 
(CCND1) (6-44% amplified), and protein kinase B (AKT3) overexpression [63, 
64].  Furthermore, tumor suppressors altered in melanoma including cyclin 
dependent kinase inhibitor 2a (CDKN2A) (30-70% deleted, mutated, or silence), 
phosphatase and tensin homolog (PTEN) (5-20% deleted or mutated), apoptotic 
protease-activating factor 1 (APAF1) (40% silenced), and tumor protein p53 
(TP53) (10% lost or mutated) have genetic alterations in melanoma [63, 64]. 
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BRAF is a key component of the Ras-Raf-MEK-ERK ([rat sarcoma]-[rapidly 
accelerated fibrosarcoma]-[MAPK/ERK kinase]-[extracellular-signal-regulated-
kinase]) pathway also known as the mitogen-activated kinase (MAP) kinase 
pathway [63, 65].  MEK and ERK phosphorylation is regulated by BRAF, and that 
MEK signaling can lead to a negative feedback mechanism to down-regulate Raf 
activity and desensitization [66, 67].  RAS and RAF regulated MEK-ERK cascade 
increases D-cyclin protein expression leading to G1 cell-cycle progression and 
cell proliferation and also activated MAP kinase interacting serine/threonine 
kinase (MNK1) regulated protein synthesis  [68, 69].  Furthermore, in RAS 
mutant melanoma cells, dependent on CRAF instead of BRAF to activate the 
MAPK kinase pathway, there is increased expression of cAMP-specific 
phosphodiesterase-4 enzymes allowing for degradation of the second 
messenger and preventing it’s inhibitory effects on CRAF [70].  Loss of 
neurofibromatosis type 1 (NF1), a GTPase activating protein that inactivates RAS 
protein which requires binding to GTP, frequently co-occurs with RAS and BRAF 
alterations in melanoma [71, 72].  ERK phosphorylation of RSK activates RSK’s 
kinase activity and promotes melanoma growth, proliferation, and cell motility [73, 
74] 
Binding of c-Kit by its ligand steel factor leads to activation of the MAP kinase 
pathway [75, 76].   This MAPK pathway activation then leads to MITF 
phosphorylation, which promotes cell survival and differentiation [75].  
Furthermore, aberrant c-KIT receptor and other receptor tyrosine kinases 
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activation, via NRAS leads to phosphoinositide 3-kinase (PI3-K)-AKT pathway 
activation, and subsequent downstream activation of mechanistic target of 
rapamycin (mTOR), which collectively leads to cell proliferation and survival 
signaling, inhibition of BAD, which leads to inhibition of apoptosis, and inhibition 
of GSK-3ß, which regulates cell proliferation [69].  Moreover, PI3K can also  
Additionally, the JAK-STAT pathway is activated by KIT [76].  Through their GDP 
to GTP exchange activity guanine nucleotide exchange factors (GEFs) activate 
Rho (Ras homologous) family GTPases, which is positively regulated by the 
PI3K pathway [69, 77], and mutations in Rho-GTPases may serve as driver 
mutations of melanoma [78].  
CDKN2A  encodes for both p16INK4a and p14ARF (p19ARF in mice) [79].  Studies by 
Krimpenfort et al showed that mutation of both alleles of p16INK4a alone did not 
affect cell proliferation, G1 cell-cycle checkpoints, or predispose mice to 
spontaneous tumor formation, but mutated p14ARF mice were predisposed to 
tumor formation.  Furthermore, if mice contained two mutated copies of p16INK4a 
and one functional copy of p14ARF (INK4a*/Δ2,3), the mice developed spontaneous 
tumors much more frequently than mice with wildtype  p16INK4 and one functional 
copy of p14ARF [80].  Not only this, but the INK4a*/Δ2,3 mice also developed 
melanomas, which frequently occur in patients with germline mutations of 
CDKN2A [80, 81].  p16INK4a regulates G1 cell cycle arrest by preventing 
hypophosphorylation of retinoblastoma protein, which is required for progressing 
to but not past the restriction point of the G1 phase of the cell cycle [82].  
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Furthermore p19ARF interacts with mouse double minute 2 homolog (MDM2) 
protein.  MDM2 normally functions to prevent p53 transactivation [83, 84] and to 
induce p53 degradation [85].  Binding of p19ARF to MDM2 disrupts this function by 
inducing MDM2 degradation and promotes p53 apoptotic response by stabilizing 
p53 potentially explaining its tumor suppressive activity [86, 87].   
Cell growth and proliferation can be regulated by the PTEN tumor suppressor by 
its antagonism of the PI3K/AKT pathway [88], regulates viability, proliferation, 
and energy usage in cells [89], and the Jun N-terminal kinase (JNK) pathway 
[90], which regulates cell proliferation [91].  Ramaswamy et al. showed that 
PTEN induces G1 cell cycle arrest, which can be rescued by a constitutively 
active AKT illustrating PTEN’s ability to regulate cell proliferation through the 
PI3K/AKT pathway [92].  Furthermore, loss of PTEN promotes melanoma 
formation and metastases in BRafV600E mice, while BRafV600E mutation alone only 
induced benign melanocytic hyperplasia and did not progress to melanoma 
formation for the first 20 months [93] 
Apaf-1 and caspase-9 are needed for p53 tumor suppressive activity, in specific 
p53 induced apoptosis [94, 95].  On the other hand, retinoblastoma protein 
inhibits the activity of E2 factor (E2F) family transcription factors, and E2F 
transcription factors increases APAF-1 expression level inducing apoptosis 
through the Apaf-1/caspase-9 cascade [95]. 
p53 protein regulates the transcription and activity of many tumor suppressive 
genes and proteins as a response to DNA damage [96-98].  Miyashita and Reed 
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discovered that p53 was an activator of proapoptotic B-cell lymphoma 2 (Bcl-2) 
protein: Bcl-2 associated X protein (BAX) utilizing a reporter gene construct for 
the BAX gene promoter [99].  Furthermore, independent of its transcriptional 
activity, activated p53 can activate the BAX gene and promote apoptosis [100].  
Other proapoptotic genes regulated by p53 are the p53 upregulated modulator of 
apoptosis (PUMA) and NOXA [101-103].  PUMA induces programmed cell death 
through binding of Bcl-2 and release of cytochrome c [101], which with 
deoxyadenosine triphosphate (dATP) allow for caspase-9 binding to Apaf-1 and 
activation of caspase 9’s leading to cleavage of caspase-3 [104], a requirement 
for DNA fragmentation, shrinking of cells, and blebbing of cells during apoptosis 
[105].  NOXA activates the Bcl-2 homologous antagonist killer (BAK) and 
promote cleavage of caspase 7 into its active form [102], which like caspase 3, is 
a major executioner of apoptosis [106, 107].   Active p53 also promotes the 
transcription of p21, a cyclin-dependent kinase inhibitor, which is needed for G1 
checkpoint arrest, the regulatory step between G1 to S transition, and G2 
checkpoint arrest, the regulatory step between G2 to M transition [108, 109].  
p21, independent of p53,  can also bind to PCNA and perform the same inhibitor 
function on G1 and G2 cell cycle progression [110].  Furthermore, p53 can 
regulate cell cycle arrest by binding with Wilms tumor 1 (WT1) protein and 
promote its transcriptional activity on the GADD45 promoter, a known G2/M cell-
cycle arrest protein [111, 112]. 
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A more recent study by Hodis et al., examined mutations in melanoma, utilizing a 
computational method in which intronic mutational data was used to control for 
passenger mutational load, allowing them to identify driver mutations in 
previously well-established cancer genes including NRAS, BRAF, PTEN, 
Mitogen-activated protein kinase kinase 1 (MAP2K1: also known as MEK) ,TP53, 
and p16INK4a, KIT amplifications, MITF amplifications, and deletions in CDKN2A 
and PTEN. New driver mutations in genes including PPP6C, RAC1, SNX31, 
TACC1, STK19 among others and loss of function mutations in ARID2 were also 
identified.  Furthermore, they investigated UVB and UVA signature mutations C > 
T and G >T, respectively and discovered that the majority of mutations in the 
MAPK pathway including majority of BRAF (V600E) mutations were not UV-
induced. On the other hand, TP53, PTEN, p16INK4a, and also in newly 
discovered genes ARID2, PPP6C, SNX31, and TACC1 were UV-induced 
mutations further elucidating the link between sun exposure as a risk for 
melanoma yet shining light to the necessity for future research on causes of non 
UV-induced mutations [113]. 




Figure 1-1:  Driver mutations and pathways in melanoma.  Major oncogenic mutations (purple circle 
with yellow text) in melanoma include BRAF activation (66% mutated), NRAS activation (15%-30% 
mutated), MITF amplifications (10-15% amplified), the cytokine receptor KIT activation (black box yellow 
text) (20%-25% mutated), cell cycle regulator Cyclin D1 (6-44% amplified), and AKT3 overexpression.  
Major tumor suppressors (green circle with yellow text) altered in melanoma including CDKN2A 
(encoding both p16 and p14) (30-70% deleted, mutated, or silence), PTEN (5-20% deleted or mutated), 
APAF1 (40% silenced), and p53 (10% lost or mutated). Dashed lines represent excluded pathway 
elements (Adapted from Lo et al., 2014)
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Therapies 
Based on staging, the recommendations vary for treatment of malignant 
melanoma.  Current recommendations by the American Academy of 
Dermatology (AAD) and European Society of Medical Oncology (ESMO) indicate 
that once a primary cutaneous melanoma, in situ, is identified local wide excision 
should be conducted [114, 115] although some argue that overall survival is not 
significantly different between narrow and wide excision of these tumors [116]. 
Furthermore a sentinel lymph node biopsy can be done to elucidate lymph node 
involvement and  partial or complete lymphadenectomy if indicated[114, 115], but 
some still question the clinical validity of complete lymphadenectomy over 
monitoring [117].  Although first-line treatment for Stage IV melanomas, or 
melanomas with distant metastasis, is still under debate, many metastatic 
melanomas, depending on mutational profiling results, are treated with 
monotherapy with or a combination of immunotherapy and kinase inhibitors [114, 
118].   
One target for immunotherapy is the protein receptor cytotoxic T-lymphocyte 
antigen-4 (CTLA-4), which down-regulates T cell immune response [119]. 
Multiple clinical trails show that, Ipilimumab, a monoclonal IgG1k antibody 
against CTLA-4, is an efficacious treatment increasing overall survival for 
patients with metastatic melanoma with a response rate of around 10%, but has 
immune-related adverse events including diarrhea, colitis, endocrine immune-
related adverse events [119-122].  Another immune therapy monoclonal, 
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nivolumab, an anti-PD1 (programmed death 1) receptor antibody, is 
therapeutically beneficial when combined with ipilimumab over ipilimumab 
monotherapy [123, 124].  Furthermore, another monoclonal antibody against 
PD1, pembrolizumab, is more efficacious in treating advanced melanomas, 
including increasing progression-free survival and overall survival, with less 
toxicity than ipilimumab [125] and also treating ipilimumab-resistant melanomas 
[126].  
Gene expression profiling has been beneficial in identifying mutations allowing 
for use of targeted therapies and also can be useful in predicting survival 
outcomes [114, 127].  Vemurafenib, PLX4032, is an analogue of the 7-azaindole 
derivative, PLX4720, that inhibits BRAF kinase activity [128, 129], and improved 
median overall survival for patients with BRAFV600E mutation [130-132]: (~13.3 
months-15.9 months) and progression free survival (~ 6.8-6.9 months) [130, 132] 
and also increases median overall survival (~14.5 months) and progression free 
survival (~ 5.9 months) for patients with BRAFV600K [130]. 
Other drugs used for treating melanoma include KIT inhibitors (imatinib, nilotinib, 
dasatinib), MEK inhibitors (selumetinib, trametinib), NRAS inhibitors (tipifarnib), 
mTOR inhibitor (rapamycin (also known as sirolimus)), and VEGFR inhibitor 
(lenvatinib).  Furthermore, drugs in the clinical or preclinical phase include PI3K 
inhibitors, AKT inhibitors, CDK2 inhibitors, Notch inhibitors and CDK4 inhibitors 
[64]. For patients with melanomas with c-Kit gene mutations or amplifications, 
Imatinib, a tyrosine kinase inhibitor, increases progression free survival (9.0 
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months) and overall survival (15.0 months) in patients who showed partial 
response [133].  Furthermore, the MEK inhibitor trametinib improves survival, 
both progression-free (4.8 months) and overall, in BRAF mutant metastatic 
melanoma [134].  The NRAS inhibitor, tipifarnib, as a single agent, lacked 
response for treating NRAS mutant metastatic melanoma [135], but MEK 
inhibitors are efficacious in treating NRAS mutant metastatic melanoma [136].  
Furthermore, a combination of the VEGFR inhibitor, bevacizumab, and mTOR 
inhibitor, everolimus, is efficacious in treating metastatic melanoma [137].  Based 
on molecular profiling, absence of BRAF mutations, NRAS mutations, or 
presence of gene expression signatures of immune related genes was predictive 
to increasing median overall survival [138].  Even with the availability of many 
different therapies for melanoma, there is still a need for novel therapies that are 
efficacious in a larger number of patients and overcome resistance. 
 
Skin Cancer and Ultraviolet Light 
There is a causal relationship between sun/ultraviolet light exposure and the 
most prevalent forms of skin cancers [18-20, 139].  Sun sensitive fair individuals 
with decreased ability to tan have an increased risk of developing skin cancer 
[20].  One explanation for this increase incidence is that ultraviolet light is more 
likely to cause DNA photodamage, including cyclobutane pyrimidine dimers, in 
light skin individuals than dark skin [140, 141]. Electromagnetic radiation ranging 
from 300 nm to 600 nm wavelength penetrates through the epidermis 
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encompassing both the ultraviolet A (UVA) (315 nm - 400 nm) and ultraviolet B 
spectra (UVB) (280 nm – 315 nm) [142].  Ultraviolet light causes oxidative DNA 
base damage, 7,8-dihydro-8-oxoguanine, [143] cyclobutane pyrimidine dimers 
[144-146] and subsequent cytosine deamination [144, 145], (6-4) photoproducts 
[146] and cell cycle changes [147, 148].  
 
Ultraviolet Radiation Induced Melanogenesis 
UV induced DNA damage initiates the normal physiological tanning process in 
keratinocytes by upregulating the expression of p53 protein.  The upregulation of 
p53 protein induces an increase in pro-opiomelanocortin (POMC) gene 
transcription in keratinocytes [149].  POMC is cleaved to multiple peptide 
hormones including: melanocyte stimulating hormones (MSH) [149-151], 
adrenocorticotropic hormone (ACTH) [150, 151], and β-endorphin [149, 152].  
Normal human melanocytes express the g-protein coupled melanocortin 1 
receptor (MC1R)[153, 154].  Alpha-MSH and ACTH have equal affinity to bind 
MC1R and potency in stimulating MC1R melanogenic activity [155] and there is 
some affinity and potency for β-MSH and limited binding and transient effect of 
gamma-MSH [154, 155] for MC1R but not β-endorphin [154].  Alpha-MSH [156] 
[1, 157] and ACTH [156, 158] can induce melanin production.  Binding of these 
hormones to MC1R increases cAMP production [1, 155, 156].  cAMP activates 
protein kinase A (PKA), and activated PKA phosphorylates the transcription 
factor cAMP-response-element-binding protein (CREB) [159, 160].  CREB then 
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increases the transcription of microphthalmia-associated transcription factor 
(MITF) gene, a master regulator of pigment related genes including tyrosinase 
[161, 162].  Tyrosinase catalyzes the conversion of L-tyrosine to DOPA and 
DOPA to DOPAquinone, which through multiple subsequent reactions, some 
catalyzed by the MITF target’s DCT and TRP1, converts into eumelanin [148, 
163].  Tyrosinase is also needed for pheomelanin production, which occurs in the 
presence cysteine and absence of DCT and TRP1 [148, 163].  Dark pigment 
melanin is photoprotective against ultraviolet light [164, 165], and the main site of 
filtration of ultraviolet light in fair skin is in the stratum corneum while in black skin 





Structure and Binding 
The MITF family consists of 50-80 kDa proteins with basic helix-loop-helix 
structure and belongs to the MiT family of transcription factors [166, 167], which 
also includes TFE3, TFEB, and TFEC [166].  MITF with it’s basic helix-loop-helix 
structure [168] acts as a positive transcription factor of pigment related genes by 
recognizing and binding DNA at a sequence upstream from the TATA-box known 
as the M-box (GTCATGTGCT) [166, 169] and a sequence downstream of the 
TATA-box, known as the conserved E-box (CATGTG) [169, 170] as a 
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homodimer or a heterodimer with TFEB, TFEC, or TFE3[166].  Myc family 
proteins also share this basic helix-loop-helix structure [171].  Furthermore, one 
of MITF’s leucine zippers contains a kink that restricts the transcription factor to 
preferentially bind to other basic helix-loop-helix structures [172].  The 10 
different MITF isoforms (A, B, C, CX, D, E, H, J, M, MC) arise from splice 
variants of ten different promoter activations [167, 173-175].  The expression of 
the M-MITF is driven by the melanocyte specific M-promoter [176].   
 
Regulation 
Transcriptionally, MITF is regulated by multiple different signaling networks 
including α-MSH-cAMP-CREB, PAX3-SOX10-CREB, Wnt3-β-catenin-BRN2, and 
TNFα-IKK-NFkB and other upstream proteins such as TNFα, TGFβ and FOXD3 
[167].  Through the up-regulation of the second messenger cAMP, α-MSH 
activation leads to the induction of CREB signaling allowing for an increase in 
transcription of M-MITF and melanogenic programming [161, 162, 177], a 
pathway activated in response to DNA damage during normal physiological 
tanning [1].  Moreover PAX3 and SOX10 are mutated in the WS1/WS3 [178, 179] 
and WS4 [180], respectively, classifications of Waardenburg-Hirschsprung 
syndrome, an autosomal dominant disorder that is characterized by deafness 
and altered pigmentation in skin, eyes and hair [181]. Mutations in MITF have 
also been associated with Waardenburg-Hirschsprung syndrome and are seen in 
WS2 [182].  Due to all three genes association with Waardenburg syndrome with 
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similar symptoms, Bondurand et al investigated the interaction of PAX3, SOX10, 
and MITF.  They discovered that alone PAX3 and SOX10 could induce the 
transcription of MITF, 10 fold and 500 fold respectively, but when co-expressed 
could synergistically increase the transcription of MITF 1500 fold [183] but there 
is still controversy over this effect [184].  Furthermore, tissue specific response of 
CREB transcriptional activity on the M-MITF promoter to cAMP is dependent on 
SOX10 transactivation [185], and PAX3 is also dependent on CREB to regulate 
MITF expression [186].  Furthermore, SMURF2 increases PAX expression [187].  
In skin, the expression of PAX3 can be inhibited by TGF- β through SMAD 
proteins [186].  Furthermore, TGF- β/SMAD can repress M-MITF gene 
expression [187] through GLI2 binding to a KLF binding site in the M-MITF 
promoter, and TGF- β alone can repress PKA activity and subsequently 
decreases phosphorylation of CREB [188].  Expression of BRN-2 (also known as 
N-OCT3 and POU3F2) is up-regulated in RAF amplified melanomas and is 
dependent on ERK phosphorylation by MEK and also positively regulated by the 
Wnt/ β-catenin pathways.  Furthermore, Brn-2 regulates proliferation in BRAF 
mutated melanomas [189].  Furthermore, the transactivation of LEF-1 and β-
catenin by Wnt-3a protein can also increase M-MITF expression [190]. 
Post-translationally, glycogen synthase kinase 3 (GSK3) can phosphorylate MITF 
on Ser298 and increase it’s binding to TYROSINASE promoter [191].  The 
immune microenvironment also plays a role in regulating MITF expression.  
Smith et al. demonstrated that TNFα released by macrophages induces MITF 
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expression in an IKK-NF and NFkappaB pathway dependent manner [192].  
Furthermore Forkhead box D3 (FOXD3), which can be suppressed by BRAF 
amplification [193], is shown to confer resistance to BRAF inhibitors potentially by 
up-regulating MITF expression [193, 194].  Onecut-2 (OC-2) can bind MITF gene 
promoter and increase MITF expression, and inhibition of binding of OC-2 can 
cause a 75% decrease MITF promoter activity [195].  Instead its usual activity of 
binding directly to DNA, M-MITF can also activate the M promoter of MITF by 
transactivating LEF-1, which has binding sites present on the M-promoter, 
leading to an increase in M-MITF expression [196] 
Post-translationally MITF can be have multiple protein modifications including 
phosphorylation, ubiquitination, acetylation, and sumoylation that can alter its 
transcriptional activity and stability [167].   M-MITF can be phosphorylated on 
Serine 73 (Ser73) via c-KIT activation of the MAP kinase pathway allowing for an 
increase in transcriptional activity on the promoter of its target tyrosinase [75]. 
Subsequently, it was established that c-Kit signaling not only triggers brief 
transcriptional activation through phosphorylation at Ser73 of MITF but also 
stimulates phosphorylation at Serine 409 through another MAPK pathway target, 
p90 Rsk-1, which promotes ubiquitination and subsequent degradation of MITF. 
[197]  Glycogen synthase 3 can increase MITF binding to the TYROSINASE 
promoter by phosphorylating MITF at Serine 298 [191], but GSK3 can also play a 
contradictory effect by phosphorylating MITF at Serine 397 (Ser397), Serine 401 
(Ser401), and Serine 405 (Ser405), which decreases MITF stability and may 
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target MITF for proteosomal degradation [198].  Wnt signaling can stabilize MITF 
through inhibition of phosphorylation at S397, S401, and S405 by glycogen 
synthase kinase 3 (GSK3) [198].  Furthermore this leads to a potential positive 
feedback loop for Wnt signaling due to increased expression of late endosomal 
proteins including Rab 7, LAMP1, and CD63 that allow for relocalization of Wnt 
destruction complex components, which decreases Wnt degradation [198].  Like 
MITF, Wnt signaling can also regulate cell proliferation and this positive feedback 
loop created by Wnt activation may further promote cell proliferation [199, 200].  
Furthermore, lysine 201 is critical for targeting MITF for degradation by the 
ubiquitin conjugating enzyme hUBC9 [201]. Sumoylation of MITF can occur on 
Lysine 182 (K182) and Lysine 316 (K316) and causes repression of 
transcriptional activity at promoters with multiple MITF binding sites such as DCT 
and TRPM1 promoter, and although there is some debate on the matter, this 
sumoylation at K316 may be dependent on protein inhibitor of activated STAT3 
(PIAS3) [202, 203].   
 
Target Genes 
The phenotypic consequence of MITF mutation was first discovered by Paula 
Hertwig in 1942 after isolating mouse mutants post x-ray irradiation with “albino” 
coats and unpigmented eyes and reduced eye size leading to the gene name 
“Microphthalmus”  [204, 205].  The microphthalmia (mi) locus altered in these 
mice was later identified in 1993 by Hodgkinson et al. [168].   MITF is known to 
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regulate multiple target genes in melanocytes including those related to 
pigmentation, differentiation, motility, apoptosis, cell cycle progression, and 
endolysosomal formation [173, 198].  Both mouse and human studies show that 
melanocyte specific M-MITF [176] is a master regulator of pigment-related genes 
including TYROSINASE [162, 169, 170, 206-209] and tyrosinase-related protein 
1 (TRP-1) [207, 208, 210] via the cAMP pathway [1, 162, 209].  Furthermore, 
MITF also regulates other pigment related genes including the transient receptor 
potential cation channel (TRP) subfamily M member 1 (TRPM1) also known as 
MELASTATIN-1 [211], which is also critical for normal melanocyte pigment 
production [212] and Dopachrome Tautomerase (DCT) also known as 
tyrosinase-related protein-2 (TRP-2) [213]. MITF controls differentiation gene 
expression including Melan-A/Melanoma Antigen Recognized by T-Cells 1 
(MLANA)/(MART1) [214], and Silver Locus Protein Homolog/pre-melanosome 
protein 17/glycoprotein 100 (SILV)/(PMEL 17)/(GP100) [214], and absent in 
melanoma 1 protein (AIM1) [215].  MITF also positively regulates the 
transcription of hepatocyte growth factor (HGF) receptor c-met, which is needed 
for HGF-dependent matrix invasion [216].  MITF also regulates cyclin dependent 
kinase 2 (CDK2) expression, which regulates cell growth and cell cycle 
progression [217].  Furthermore, MITF positively regulates expression of T-box 
protein 2 (TBX2) [218], which represses cyclin dependent kinase inhibitor 2a 
(CDKN2a)(p19ARF) [219], and CDKN2a binds to cyclin dependent kinase 4 
(CDK4) and cyclin dependent kinase 6 (CDK6) and prevents their binding and 
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inhibition of retinoblastoma 1 (RB1) inducing G1 cell cycle arrest [220].  MITF can 
also promote the expression of p21Cip1 (CDKN1A) through association with RB1 
[221] and increases in p16(Ink4a) expression, which subsequently leads to Rb 
hypophosphorylation [222].  Increased protein expression of p21Cip1 (CDKN1A) 
and  p16(Ink4a) leads to cell cycle arrest [221, 222].  MITF can also positively 
regulate the antiapoptotic protein B-cell lymphoma 2 (BCL2) [223] and pro-
angiogenic hypoxia-inducible factor 1-α (HIF-1-α) expression [224].   
Thus, MITF regulates many cancer relevant genes and alterations in its 
expression may be detrimental for normal cell programming.   
 
Role in melanoma oncogenesis 
MITF is amplified in 10%-20% of melanomas [2, 225].  In a study by Garraway et 
al. looking at 30 primary cutaneous melanomas, 32 metastatic tumors, and 10 
benign melanocytic nevi, MITF gene amplification is found in 10% of primary 
cutaneous and 21% metastatic melanomas, but no amplification was detected in 
benign nevi [2].  Furthermore Garraway saw a correlation between  BRAF 
(V600E) mutation and MITF amplification in melanoma cell lines [2].  However in 
a study by Ugurel et al characterizing 116 metastatic melanoma patient samples, 
there was no correlation between BRAF mutation and MITF status, yet strong 
amplification (>4 copies) of MITF was still seen in 23% of samples [225]. 
Furthermore, amplification of MITF and its transcriptional targets confer 
resistance to BRAF inhibitors and MEK inhibitors [187, 226, 227], which may be 
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due to MITF’s regulation of prosurvival and antiapoptotic genes [198, 216-218, 
223, 224].  Furthermore, this MITF upregulation is correlated with a more 
proliferative and less invasive melanoma phenotype [228] although this is not 
always the case [229].  Contrary to results reflecting high MITF conferring 
resistance to MAP kinase pathway targeting drugs, a retrospective study utilizing 
gene profiling analysis of 214 cutaneous malignant melanomas demonstrated 
that low MITF melanoma’s were resistant to targeted therapies including BRAF-
mutant metastatic melanomas to BRAF inhibitors dabrafenib and vemurafenib.  
Furthermore, although not statistically significant low MITF melanomas exhibited 
trending resistance to dabrafenib in combination with the MEK inhibitor, 
trametinib, and a MAGE-A3 vaccination, a vaccination against this peptide 
specific to melanomas, which is not expressed in normal human tissue apart 
from testis [127, 230, 231]. Invasive/drug resistant low-MITF melanoma cells 
display high AXL expression [232, 233].  Furthermore Khoja et al demonstrated 
that both MITF high cells and MITF low cells can be detected in circulating 
melanoma cells [234], which can be explained by coordination between the two 
types of cells to invade during invasion and metastasis [235].  Furthermore, 
switching of melanomas from high to low or low to high MITF status may be due 
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LKB1-SIK-CRTC-MITF Axis 
Due to MITF’s critical role as both a major transcriptional regulator of pigment-
related genes and also, when amplified, a driver of melanoma [113, 149], a 
deeper understanding of mechanism of MITF regulation is needed.  Although 
understanding of upstream regulators of MITF expression is vast, some 
pathways still remain mechanistically undefined.  One upstream pathway that 
warrants further characterization is the LKB1-SIK-CRTC-MITF pathway.   Liver 
kinase B1 (LKB1) is a master regulator of AMPK and AMPK related kinases, and 
one downstream target of LKB1 is salt-inducible kinase (SIK) [237].  In mice 
SIK2, one of the three SIK isoforms, modulates MITF expression through 
regulation of CRTC2 cellular localization and subsequent CRTC2 binding to 
CREB, the transcriptional regulator of MITF [238]. Furthermore, in non-
melanocytic cells, LKB1 modulates CRTC localization.  In mouse livers void of 
LKB1, dysregulation of CRTC2 localization by dephosphorylation allowed for an 
increase in nuclear localization of CRTC2 and increased the expression of the 
gluconeogenesis regulator peroxisome proliferator-activated receptor-gamma 
coactivator 1α (PGC-1α) resulting in hyperglycemia [239].  Not only this but in 
HELA cells, LKB1 was characterized to modulate the SIK-CRTC-CREB axis 
[240].  Furthermore, SIK2 knockout mice show increased melanogenic 
programming [238] and LKB1 loss in BrafV600E mice have increased melanin 
production [241].  This hints at the possibility that LKB1 can also modulate MITF 
expression through SIK-CRTC axis regulation (Figure 2).  Although the 
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phenotypic consequence of LKB1 and SIK dysregulation has previously been 
established in melanocytes, how these two kinases interact as a mechanism for 
this phenotype and how they interact to possibly drive melanoma remains to be 
elucidated.   
 
LKB1  
Regulation, Structure and Binding 
LKB1 is expressed ubiquitously but principal expression occurs in epithelial 
tissue and in the seminiferous tubules of the testis in adult human tissue [242].  
There is higher expression of LKB1 in fetal human tissue than in adult human 
tissue [242].  Hypermethylation of 5’-CpG islands of the LKB1 gene leads to gene 
silencing [243-245].  In breast cancer cells, 17 β-estradiol negatively regulates 
LKB1 expression by binding to the LKB1 promoter [246].  Furthermore, estrogen 
Figure 1-2:  LKB1-SIK-CRTC-MITF Axis.  Proposed mechanism of LKB1’s regulation of the SIK-CRTC-
MITF axis (Adapted from Altarejos and Montminy, 2011)
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receptor (ER)-α binding to LKB1’s promoter is ligand independent, but no 
correlation was found with ER-α status and LKB1 expression in breast tumors 
[246].  In another study it was demonstrated that ER-α knockdown in breast 
cancer cells increased the level of LKB1 expression supporting ER-α’s 
suppressive role on the LKB1 promoter [247].  Moreover, other sex hormones 
can regulate LKB1 expression.  Male sex hormones testosterone and 
dihydrotestosterone can decrease LKB1 expression in adipocytes, and unlike 
what was seen in breast cancer cells, 17-β-estradiol increases LKB1 expression 
in adipocytes [248].  In non-small cell lung cancer cells fibronectin inhibits LKB1 
expression and decreases LKB1’s target kinase AMPK’s phosphorylation [249].   
Post-translationally, LKB1 be modified by phosphorylation, deacetylation, 
prenylation, and ubiquitination [250].  Protein kinase A (PKA) [251-253] and PKC 
[254] can phosphorylate LKB1. Murine LKB1 can be phosphorylated at Serine 
431 by PKA [252, 255] and Serine 428 in human, rat, and mouse by PKC [254]  
PKA’s phosphorylation of LKB1 can be the result of glucagon pathway activation 
in rat livers [253].  P70 ribosomal S6 kinase (S6K1), MAPK activated mitogen- 
and stress-stimulated protein kinase (MSK1), ERK activated p90RSK can 
phosphorylate LKB1 at Serine 431 [255].  Furthermore, phosphorylation of LKB1 
at Threonine 336 can inhibits it’s growth suppressive activity [256].  Additionally 
Threonine 366 can be phosphorylated by the DNA damage response proteins, 
DNA-dependent protein kinase (DNA-PK) and ataxia telangiectasia mutated 
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kinase (ATM) [257].  LKB1 can also be phosphorylated on Serine 31 and Serine 
325 with unknown functional outcome [256]. 
Mouse LKB1 can also be prenylated at cysteine 433, which regulates its cell 
membrane localization [252, 255], and prenylation of LKB1 does not regulate 
LKB1’s growth suppressive activity [255].   
It has been demonstrated that LKB1 can be acetylated on lysine residues in 
multiple different cell lines and tissues [258, 259].  Furthermore, it was shown 
that through Sirtuin 1 (SIRT1) deacetylase can stimulate AMPK phosphorylation 
and signaling in human hepatocytes and HEK293 T cells and also MARK1 
phosphorylation in human hepatocytes by deacetylating LKB1 [258, 259].  On the 
other hand, in pig aortic endothelial cells SIRT1 deacetylation of LKB1 can play 
an opposing role and promotes ubiquitination and proteasome-mediated 
degradation of LKB1 decreasing LKB1 anti-proliferative activity [260]. Other 
regulators of LKB1 degradation and also activity are heat shock protein 90 
(Hsp90) and cell division cycle 37 (Cdc37) [261].  Complexed together Hsp90-
Cdc37 can bind LKB1 preventing it’s catalytic activity yet keeping LKB1 stable. 
When Hsp90 dissociates from LKB1, heat shock proteins Hsc70 and Hsp70 
complex and E3 ubiquitin ligase carboxyl terminus of Hsc70-interacting protein 
(Hsp/Hsc70-CHIP) are recruited, which promotes degradation of LKB1 [261].  
LKB1 can also be activated by STRADα and MO25α when pseudokinase 
STRADα bound to the armadillo repeat scaffolding-like protein MO25α binds the 
LKB1 kinase domain [262] in a phosphorylation independent manner, which is 
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unlike other regulatory kinases [263, 264].  MO25α binds to STRADα regulatory 
helix [262].  In its heterotrimer structure, LKB1 has a stabile globular shape with 
STRADα pseudokinase domain bound to LKB1 activation loop and MO25α is 
also in contact with the LKB1 activation loop, rendering LKB1 active independent 
of phosphorylation [262].  Furthermore the LKB1-STRADα-MO25α complex can 
translocate from the cytoplasm to the nucleus where activated LKB1 can perform 
its kinase activity [263].  LKB1 can also complex with polyploidy-associated 
protein kinase (PAPK) [also known as STE20-related kinase adaptor beta] and 
MO25α, or heat shock protein (HSP90) and CDC37 and these complexes also 
have cytoplasmic translocation activity like LKB1-STRADα-MO25α [265-267]. 
 
Target Proteins 
LKB1 positively regulates AMPK and multiple different AMPK-related kinases 
including MARK1, MARK2, MARK3, MARK4, SIK1, SIK2, SIK3, SNRK, NUAK1, 
NUAK2, BRSK1, and BRSK 2 by phosphorylating the T-loop threonine residue 
[237]  On the other hand, another AMPK-related kinase,  maternal embryonic 
leucine zipper kinase (MELK), can autophosphorylate it’s T-loop threonine and 
it’s kinase activity may be dependent or independent of LKB1 [237, 268].  Other 
AMPK-related kinases such as NIM1 and testis-specific serine/threonine kinase-
1 (TSSK1) are not phosphorylated by LKB1 [269].   
LKB1 can phosphorylate AMPK within the alpha subunit at Threonine 172 [264, 
270-272] allowing for AMPK activation [270] in multiple different human cell and 
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mammalian cell lines [270-272].  LKB1 activated AMPK phosphorylates acetyl 
CoA carboxylase (ACC) on Serine 79 inactivating ACC [271], which is an 
anabolic pathway [273].  AMPK can inhibit enzymes needed for other anabolic 
pathways including glycerol phosphate acyl transferase, which regulates 
triacylglycerol synthesis, and HMG-CoA reductase, which regulates cholesterol 
biosynthesis, and promote catabolic pathways that would generate ATP [273]  
Shaw et al proposed that LKB1’s regulation of AMPK protects against apoptosis 
in a high AMP environment because loss of LKB1 lead to cell death when cells 
were stimulated with AMP [271]. 
LKB1 can become activated as a cellular stress response such as glucose 
deprivation, which subsequently activate AMPK leading to G1 cell cycle arrest 
through stabilization and activation of p53 by both AMPK and LKB1.  This initially 
leads to cell survival under the low glucose stress and eventually leading to cell 
cycle arrest [274-276].  Furthermore, LKB1 in a p53 dependent manner is 
recruited to the p21/WAF1 promoter, a target of p53 gene regulation, allowing for 
it’s activation by an unknown mechanism and leading to G1 phase cell cycle 
arrest [276].  Furthermore, activated AMPK regulates multiple different anabolic 
and catabolic proteins [274].  Catabolic pathway proteins positively regulated by 
AMPK include ULK1 (autophagy), PGC1α and SIRT1 (mitochondrial biogenesis 
oxidative metabolism), PFKFB2/3 (glycolysis) and also fatty acid uptake and 
glucose uptake by unknown mechanisms [274].  AMPK can also negatively 
regulate ACC2 (fatty acid oxidation) and TBC1D1 (glucose uptake [GLUT 4]), 
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which regulate catabolic pathways [274].  Anabolic pathway proteins inhibited by 
AMPK include ACC1 (fatty acid synthesis), HMGR (sterol synthesis), SREBP1c 
and ChREBP (transcription of lipogenic genes), TIF-1A (transcription of 
ribosomal RNA), mTORC1 (protein synthesis, translation of ribosomal proteins 
and HIF 1α  [transcription factor that regulates angiogenic and erythropoietic 
genes] [274, 277].  In colon cancer cells, AMPK inhibits cyclooxygenase-2 
(COX2), a positive regulator of cell growth and proliferation [278], and rescue of 
LKB1 expression in lung cancer cells decreases COX-2 expression [279].  LKB1 
activated AMPK can inhibit proliferation and decreased lung metastasis of 
xenografted breast cancer tumors through AMPK down-regulating matrix 
metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), vascular 
endothelial growth factor (VEGF) [280].  mTORC1 inhibition can also induce 
autophagy [281], and LKB1 deficient mouse tumors have both increase mTORC1 
expression and HIF-1 expression [282].  
Furthermore, LKB1 phosphorylation of microtubule-associated 
protein/microtubule affinity regulated kinases (MARK) occurs on the activation 
loop threonine activating MARK and allowing for regulation of tubulin 
polymerization through phosphorylation of Tau by MARK  [283, 284].  
Phosphorylation of microtubule associated Tau by LKB1 activated MARK 
reduces Tau’s affinity for microtubules and in turn allows for tubulin 
polymerization suppression [283-285]. 
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In Hela cells, sucrose non-fermenting related kinase (SNRK), which is 
predominantly expressed in testis of rat, is phosphorylated on the Threonine 173 
of the T-loop by LKB1 in complex with STRAD and MO25 [269]. 
The predominantly nuclear located SNARK/NUAK2 (SNF1/AMP kinase-related 
kinase/NUAK family kinase 2) [286] can be activated by phosphorylation of 
Threonine 208 by LKB1 [237], and is highly expressed in neonatal rat 
keratinocyte cell lines and human hepatocellular carcinoma cell lines (H4IIE) 
[287].  SNARK/NUAK2 phosphotransferase activity may be dependent or 
independent of AMP. Glucose deprivation, ultraviolet B, and oxidative stress 
serve as positive regulators of SNARK/NUAK2 activity while metformin 
negatively regulates SNARK/NUAK2 activity [287].  Furthermore, TNFα 
increases SNARK/NUAK2 expression and SNARK/NUAK2 can phosphorylate 
myosin phosphatase subunit 1 (MYPT1), which serves as a phosphatase of 
myosin light chains and can possibly regulate cell division [288, 289]. 
BRSK 1 (brain-specific serine/threonine kinase 1) and BRSK 2 (brain-specific 
serine/threonine kinase 2) (Also known as SAD-B (synapses of amphids 
defective B kinase) and SAD-A (synapses of amphids defective A kinase, 
respectively), expressed in mouse forebrain, can be phosphorylated on threonine 
189 and Threonine 174, respectively, by LKB1, increasing their kinase activity 
[237, 290].  In the cerebral cortex of mice, BRSK 1 and BRSK2 activation and 
phosphorylation of microtubule-associated proteins is needed for neuronal 
polarization [291]. 
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LKB1 induces apoptosis through p73 in pancreatic cancer cells [243], JNK 
pathway in drosophila [292], TRAIL and death-associated protein 3 (DAP3) in 
osteosarcoma cells [293].  LKB1 may also be protective against apoptosis due to 
it’s regulation of AMP:ATP since increased AMP in LKB1 deficient cells is 
proapoptotic [271].    
 
Role in Cancer Biology  
LKB1 mutations can be detected in majority of patients with Peutz-Jegher 
syndrome, which is characterized by mucocutaneous melanin pigmentation, 
hamartomatous polyps (occurring in stomach, small intestines, colon, and 
rectum), and an increased risk for developing multiple cancers [294, 295]. 
Increased LKB1 expression and loss of LKB1 expression occurs in malignant 
tumors [242].  LKB1 loss occurs in 19% of human squamous cell carcinomas 
[296], 34% of human lung adenocarcinomas [296], and 20% of human cervical 
cancers [297].  LKB1 can regulate multiple different pathways many of which 
lead to tumor suppression including pathways that suppress cancer cell growth, 
induce cancer cell death, and inhibit cancer cell metastasis [250].  Silencing of 
LKB1 gene is seen with 5’-CpG island hypermethylation in sporadic colorectal 
cancer [245] and pancreatic carcinoma cells [243].   
Decreased LKB1 expression is seen in estrogen receptor (ER)-positive breast 
tumors, and although no correlation has been found with LKB1 status and ER 
status in these tumors, this effect may partially be due ER regulatory effects on 
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the LKB1 promoter [246].  Furthermore, fibronectin, which negatively regulates 
LKB1 expression [249], and also increase non-small cell lung carcinoma growth 
and decreases apoptosis [298] through the downstream regulatory target of 
LKB1 signaling, cyclooxygenase-2 [279, 298].  LKB1 can be a negative [271] or 
positive regulator [243, 292, 293] of apoptosis demonstrating how it could be 
beneficial for tumors to have either amplification or loss of LKB1. 
Also, loss of LKB1 may give a tumors metastatic advantage since LKB1 inhibits 
the expression of proteins needed for invasion and migration of tumors [280] 
Furthermore, LKB1 regulated pathways are currently studied for therapeutic 
approaches for tumor suppression [250].  Drugs shown to have some in vivo or in 
vitro efficacy include celecoxib (COX-2 inhibitor) [299], rapamycin (mTOR 
inhibitor) [300], metformin [301] and resveratrol [302] (AMPK activators)[250]. 
 
LKB1 and melanoma    
In human melanoma cell lines, A375 cells, the synthetic nucleotide-like TLR7/8 
ligand imiquimod depletes ATP, inducing LKB1 activation of the AMPK pathway 
by phosphorylation which subsequently leads to a reduction of the Bcl-2 family 
member Mcl-1, which was previously shown to inhibit apoptosis induced by 
imiquimod in basal cell carcinoma cells [303], and cell apoptosis [304]. 
In melanomas with BRAF (V600E) mutations with activation of the MAP kinase 
pathway, there is suppressed LKB1 kinase activity by phosphorylation by ERK 
and Rsk [305] leading to suppression of AMPK activity.  Expression of a LKB1 
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(S325A/S428A) that is incapable of being phosphorylated by ERK and Rsk 
inhibits cell proliferation and decreases growth in soft agar assay, a method used 
to determine anchorage-independent growth [306]. Furthermore, melanocytic 
nevi from BRAF (V600E) mice with loss of LKB1 exhibited higher rates of 
proliferation compared to BRAF (V600E) oncogene-induced senescent nevi 
alone, but no melanoma formation was observed in LKB1/BRAFV600E mice, and 
treatment with mTOR inhibitor rapamycin lead to restoration of senescence [241].  
Furthermore, LKB1/BRAF mice with loss of Cdkn2a, which normally inhibits 
metabolism and cell cycle progression, lead to melanoma formation [241].  
Combination of a BRAF inhibitor PLX4720 and phenformin, a biguanide, which 
act in an AMPK-dependent [307] and independent [308] inhibitor of mTOR 
signaling, induces tumor regression in Colo829  and A375 melanoma 
xenografted mice and BRAF(V600E)/PTENNULL mice [309], while metformin 
monotherapy is efficacious in only MDA-MB-435 BRAF mutant melanoma 
xenografted mice [310].  Furthermore, the BRAF inhibitor (PLX4032) in 
combination with metformin inhibits cell proliferation in BRAFV600E melanoma 
cell lines [311].  Vincristine induces apoptosis in B16 melanoma cells by 
increasing ROS [312], leading to LKB1 activation and activation of LKB1’s 
downstream kinase target AMPK, which induces apoptosis through p53 
phosphorylation [313].  GDC-0980, a PI3K inhibitor and mTORC1 inhibitor, was 
efficacious at decreasing tumor volume of A549 nonsmall cell lung carcinoma 
cells with K-RAS mutation and LKB1 loss [314].   
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Additionally, in K-RAS mutant mice with loss of LKB1 there was a decrease in 
melanoma free survival as compared to K-RAS mutation alone.  Similar 
melanoma free survival in K-RAS mutant mice with p53 knockout and LKB1 
deficient melanomas was observed. On the other hand with LKB1 loss there was 
an increase in migratory potential in vitro, which was dependent on Yes activity 
[315].  LKB1 suppresses Yes-associated protein 1 (YAP1) nuclear translocation 
in gastric cancer cells allowing for inhibition of proliferation of these cancer cells 
[316], and YAP1 is amplified in 4% melanomas and correlates with decreased 
patient survival [317], but YAP1 link to LKB1 activity in melanoma remains to be 
deduced.  In melanoma, loss of LKB1 in KRAS mouse melanomas leads to 
disturbance of detection extracellular matrix bound cues (collagen and fibronectin 
gradients), also known as haptotaxis, through the AMPK-related MARK1 kinase, 
which may explain in part how loss of LKB1 increases melanoma invasiveness 
and metastatic potential  [318].  In NRAS(Q61R)/p16INK4a knockout mice, loss of 
LKB1 lead to increase metastasis [319].   
 
SIK 
Regulation, Structure, Binding 
Salt inducible kinase (SIK) was first discovered in adrenocortical tissues of rats 
fed a high salt-diet utilizing subtractive hybridization [320].  Furthermore, 
adrenocorticotropic hormone treated Y1 mouse adrenocortical tumor cells 
increase the expression of this serine/threonine kinase.  SIK negatively regulates 
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the expression of cholesterol chain cleavage cytochrome P450, and such an 
inhibitory effect was not observed when kinase defective SIK (K56M) was 
transfected into Y1 cells [321].  In mouse skeletal myocytes, CREB can stimulate 
SIK1 expression [322].  In mouse adrenocortical tumor cells, adrenocorticotropic 
hormone (ACTH) and PKA can stimulate the mRNA expression of salt-inducible 
kinase [321].  Increases in cellular cAMP levels can inhibit SIK2’s activity through 
phosphorylation by cAMP activated protein kinase A (PKA) and prevents SIK2 
inhibitory effects on CRTC2 nuclear localization by preventing CRTC2’s 
phosphorylation by SIK2 [323].  Furthermore, increases in cellular calcium levels 
can also lead to CRTC2 dephosphorylation at the SIK phosphorylation site, 
through activation of the serine/threonine phosphatase calcineurin [323].  PKA 
can phosphorylate SIK1 on Serine 577 inhibiting SIK1’s phosphorylation of 
CRTC and increasing cytoplasmic localization of SIK1, and Serine 577 can also 
be autophosphorylated after LKB1 phosphorylation at Threonine 182 in the A-
loop [240].  SIK activation is dependent on phosphorylation of the T-loop 
threonine 182 [237, 240, 324].  In COS-7 cells, derived from monkey kidney, 
autophosphorylation of Serine 186 and LKB1 were required for SIK1 kinase 
activity [324] 
Target Proteins 
SIK can regulate CRTC activity through phosphorylation after being activated by 
LKB1, which increases CRTC’s cytoplasmic localization and prevents activation 
of CRTC’s binding target CREB [240].  SIK can also phosphorylate class II 
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histone deacetylases (HDACs) (histone deacetylase 5) inactivating the HDACs 
leading to increased activity of motet enhancer factor 2 and muscle-specific gene 
expression in mouse myocytes [322].  Overexpression of SIK in mouse 
adrenocortical tumor cells decreases the level of cholesterol side-chain cleavage 
cytochrome P450 and steroidogenic acute regulatory protein mRNA [321]. 
In immortalized human mammary epithelial cells, with activated PI3K, SIK1 was 
shown to be a positive posttranslational regulator of p53 [325], and activated 
PI3K was previously shown to be needed to overcome programmed cell death 
due to cell detachment from extracellular matrix, also known as anoikis, when 
p53 was lost [326, 327].  Furthermore, loss of SIK1 decreased p53 dependent 
anoikis, apoptosis induced by cell detachment, in cells in suspension culture, and 
when cells expressing shSIK1 were injected into mammary fat pads, lung 
metastasis was observed without primary tumor observation [325].  Furthermore, 
LKB1’s regulation of p53-dependent anoikis was dependent on SIK1, and 
knockdown of SIK in A549 lung cancer cells increased metastatic and invasion 
potential in matrigel invasion assay and experimental metastasis assays [325].   
SIK2 can also phosphorylate the centrosome linker-protein C-Nap1, allowing for 
C-NAP1 dissociation from centrosome leading to centrosome separation during 
mitosis [328].  Moreover, in ovarian cancer, SIK3 amplification was shown to 
promote cell cycle progression through the negative regulation of p21Waf/Cip1 
expression and increasing the activity of PI3K [329] 
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Role in Cancer Biology  
SIK1 negatively regulates invasion and metastasis [325].  Furthermore, in breast 
cancers loss of SIK1 correlates with poor clinical outcomes and lower SIK1 
expression is correlated with higher malignant grade (associated with higher 
metastatic potential) in ovarian cancer tumors [325].  Moreover, loss of SIK2 
sensitizes in vitro and in vivo ovarian cancers to paclitaxel, a drug that may 
cause cell death by mitotic arrest or chromosome missegregation [328, 330].   
Charoenfuprasert et al. implied that SIK 3 could be used as a tumor-associated 
antigen for ovarian cancers due the fact that immunohistochemical staining for 
SIK3 showed amplification in 55% of ovarian tumors while only weak staining 
10% of adenomyosis and no staining of leiomyoma, gynecological benign 
tumors, was observed [329].  Reduction of LKB1-SIK1 signaling induces 
epithelial to mesenchymal transition (EMT) in non-small cell lung cancer cells 
through upregulation of the EMT transcription factor zinc-finger E-box binding 
protein 1 (ZEB1) [331], and another EMT transcription factor zinc finger E-box 
binding protein 2 (ZEB2) is critical for MITF expression and melanocyte 
differentiation,[332]. 
 
Significance of Research  
 Skin cancer is the most common form of cancer in the United States  
[9].  Although melanoma accounts for a small percentage of skin cancers it has a 
high mortality rate [48].  There is still a need for better understanding of the 
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molecular pathways leading to this deadly disease to help develop and improve 
treatments.  Not only this, the variance in the melanocortin 1 receptor prevents a 
significant proportion of the population from utilizing the protective effects of the 
normal tanning pathway, and there is a need for developing a method to bypass 
this pathway to induce pigmentation.   
 Our project further elucidates the role of the LKB1/SIK axis in the 
transcriptional regulation of MITF and investigates how these tumor suppressors 
effect tumorigenic transformation and proliferation in melanoma.  We also 
investigate the use of SIK inhibitors as a method to induce MC1R independent 
pigmentation.  Collectively we believe this work has identified a new pathway of 
melanoma oncogenesis, and provides a method for topical tanning through 
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Chapter 2:  A UV independent topical small molecule approach for melanin 
production in human skin 
 
Introduction  
The incidence of nonmelanoma and melanoma skin cancers has been increasing 
in the United States over recent decades [9, 333, 334]. Epidemiological evidence 
suggests that there is a causal relationship between sun/UV exposure and the 
three major histologic forms of skin cancer:  squamous cell carcinoma, basal cell 
carcinoma, and cutaneous melanoma [18, 19, 139]. Individuals with fair skin 
and/or poor tanning ability are at higher risk for developing these malignancies 
[20], which are uncommon in darkly pigmented individuals [335]. During UV-
induced tanning, DNA damage in keratinocytes triggers p53-mediated 
transcription of the pro-opiomelanocortin (POMC) gene [149]. Proteolytic 
cleavage of POMC produces α-MSH, which binds to the melanocortin-receptor-1 
(MC1R) on melanocytes, activating adenylate cyclase. Elevated cAMP activates 
protein kinase A (PKA), which phosphorylates the cAMP-responsive-element-
binding protein (CREB) [159, 160], which in turn stimulates the transcription of 
the microphthalmia-associated transcription factor (MITF) gene [161, 162]. MC1R 
non-signaling variants are associated with lighter skin tones and red hair, and are 
linked to poor tanning responses [336]. Previously, topical application of the 
cAMP agonist forskolin was shown to rescue the cAMP-MITF-eumelanin 
pathway in Mc1r deficient mice [1]. Subsequent studies identified the 
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phosphodiesterase PDE4D3 as a key regulator of melanocytic cAMP 
homeostasis, and its suppression produced hyperpigmentation similar to 
forskolin treatment in red-haired mice [337]. However, attempts to apply both of 
these small molecule approaches to human skin have been unsuccessful, likely 
related to poor skin penetration of the active species. 
Genetic data in mice have suggested the presence of a pathway in which CREB-
regulated transcription co-activator (CRTC) positively and salt-inducible kinase 2 
(SIK2) negatively regulate MITF and pigment synthesis independently of CREB 
phosphorylation by PKA [238]. In macrophages, the small molecule SIK inhibitor 
HG 9-91-01 regulates CREB-dependent gene transcription by suppressing 
phosphorylation of CRTC [338], thereby inhibiting cytoplasmic sequestration and 
permitting its nuclear translocation.  We hypothesized that small molecule SIK 
inhibitors could be generated and optimized as topical agents capable of 








Materials and Methods 
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Materials. Salt inducible kinase inhibitors, HG 9-91-01, YKL 06-061, and YKL 
06-062 (Salt inducible kinase inhibitors were developed by Gray group and 
scaled up by Medchem Express), were dissolved in 30% propylene glycol 
(Sigma-Aldrich) + 70% 200 proof ethanol (Decon Laboratories Inc).  
 
Mice. C57BL/6J Mc1re/e mice were crossed with K14-SCF transgenic mice and 
C57BL/6J Tyrc2j/c2j were crossed with K14-SCF transgenic mice [1, 339].  Mixed-
gender adult mice were used.  All animal experiments were performed in 
accordance with institutional policies and Institutional Animal Care and Use 
Committee-approved protocols. 
 
Human Tissue Samples. Skin samples considered surgical waste were 
obtained de-identified from healthy donors undergoing reconstructive surgery 
according to institutional regulation.  
 
Quantitative real time polymerase chain reaction (qRT-PCR).  mRNA was 
extracted from cells using the RNeasy Mini Kit (Qiagen).  KAPA SYBR ® FAST 
Universal One-Step qRT-PCR Kit (KAPA BIOSYSTEMS) was used to prepare 
mRNA samples for qRT-PCR and samples were analyzed using the 7500 Fast 
Real Time PCR System (Applied Biosystems).  The relative expression of each 
gene was calculated by 7500 Fast System Software, which utilizes Ct normalized 
to mRNA levels of RPL11 to calculate relative expression.  Results are reported 
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relative to control cells.  Primer sequences used:  human M-specific MITF 
forward 5’-CATTGTTATGCTGGAAATGCTAGAA-3’, human M-specific MITF 
reverse 5’-GGCTTGCTGTATGTGGTACTTGG-3’, TRPM1 forward 5’-
ATGCCTTGAAAGACCACTCCTCCA-3’, TRPM1 reverse 5’-
TGTGGGAGTTGTTGAGCACAGAGA-3’, RPL11 forward 5’- 
GTTGGGGAGAGTGGAGACAG-3’, RPL11 reverse 5’-
TGCCAAAGGATCTGACAGTG-3’. 
 
Kinome Profiling. Kinome profiling was performed using Discover Rx 
KinomeScan ScanMAX at compound concentration of 1µM.  489 kinases were 
profiled covering over 80% of human protein kinome.  Analysis was based on 
inhibitor binding to kinases. Protocols are available from DiscoverX.  
 
Kinase activity in vitro assay.   The biochemical activities against SIK2 were 
measured by Caliper-based mobility shift assay (PerkinElmer).  For these 
experiments, full length His6-MBP-tagged hSIK2 (4 nM) was incubated with HG-
9-91-01 derivatives in buffer containing 100 mM HEPES 7.5, 10 mM MgCl2, 2.5 
mM DTT, 0.004% Tween 20, 0.003% Brij-35, 30 µM ATP, and 1.5 µM ProfilerPro 
FL-Peptide 10 (5-FAMKKKVSRSGLYRSPSMPENLNRPR-COOH, PerkinElmer, 
Catalog No. 760354) at room temperature. Reactions were quenched by adding 
20 mM EDTA (pH 8) after 1 hour, and percentage of substrate conversion was 
measured by LabChip EZ Reader II (PerkinElmer).  IC50s for SIK2 inhibition 
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were calculated using SmartFit nonlinear regression in Genedata Screener 
software suite (Genedata).  
All other in vitro kinase assay were conducted using the SelectScreen Kinase 
Profiling Service at Thermo Fisher Scientific (Madison, WI). The protocols are 
available from the Thermo Fisher Scientific website. 
 
Cell Lines.  UACC62 and UACC257 cells were obtained from the National 
Cancer Institute (Federick, MD) DTP, DCTD cell line/tumor repository.   
 
Cell Culture.  UACC257 human melanoma cells and UACC62 human melanoma 
cells were grown in RPM1 medium + 1% penicillin/streptomycin/glutamine + 5% 
fetal bovine serum.  Normal human melanocytes were grown in TIVA medium 
(HAM’s F-12, 1% penicillin/streptomycin/glutamine, 10% fetal bovine serum, 
50ng/mL 12-O-tetradecanoyl phorbol-13-acetate, 1 x 10-4 M 3-isobutyl-1-methyl 
xanthine, 1 µM Na3VO4, 1 x 10−3 M N6,2’-O-dibutyryladenosine 3:5-cyclic 
monophosphate), and were starved for 24 hours in HAM’s F-12 + 1% 
penicillin/streptomycin/glutamine before all molecular experiments. 
 
Photos.  Photos were taken using a Nikon D50 DSLR camera with a Nikon 
Nikkor 40 mm f/2.8 DX G AF-S lens.  Shutter speed ranged from 1/40 to 1/250 
and aperture ranged from F3-F8.  Ott-Lite Model L139AB lamps were used to 
create uniform lighting for photos.  
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Colorimeter Measurements. Differences in darkening of the skin were 
measured by reflective colorimetry (Commission Internationale de l’Eclairage 
[CIE] L* white-black color axis) utilizing a CR-400 Colorimeter (Minolta) calibrated 
by a calibration plate (C: Y 93.1, x .3133, y .3194) before each set of 
measurements.    
 
Mouse pigmentation experiments.  For in vivo darkening experiment, male and 
female mice ranging from 1.5-3 months old were used. For in vivo time course 
experiment, male and female mice ranging from 2.5-6 months were used.  
Animals were waxed and treated with vehicle control (30% propylene glycol + 
70% ethanol) or 37.5 mM HG 9-9-01 until uniform gross darkening was visible, 
as stated in figure legends.  Daily differences in darkening of the skin were 
measured by reflective colorimetry (when hair was re-growing, no measurement 
was taken until hair was long enough to be waxed).  Skin was harvested, fixed, 
and processed for paraffin embedding.  Sections were cut from paraffin blocks, 
and sections were stained utilizing hematoxylin and eosin (morphology) and 
Fontana-Masson (melanin).  Melanin dissolution was conducted utilizing the 
NaOH lysis method as described previously by Wakamatsu and Ito.  In the time 
course experiment, one vehicle-treated Tyrc/c;K14-SCF mouse (Day 11) and two 
vehicle-treated Mc1re/e;K14-SCF mice (Day 23 and Day 34) died due to technical 
reasons.  
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Human pigmentation experiments.  Full thickness human breast skin explants 
were cultured in petri dishes with a solid phase and liquid phase phenol red free 
DMEM medium with 20% penicillin/streptomycin/glutamine, 5% fungizone 
(Gibco), and 10% fetal bovine serum.  Explants were treated daily with vehicle or 
SIK inhibitor as indicated in figure legends.  Passive application refers to simply 
applying the treatment to skin without further rubbing or 
manipulation.  Mechanical application refers to application of agents to skin with 
further rubbing of treatment with 10 clockwise turns of a gloved cotton swab 
applicator.  Skin was harvested, fixed, and processed for paraffin embedding.  
Sections were cut from paraffin blocks, and sections were stained utilizing 
hematoxylin and eosin (morphology) and Fontana-Masson (melanin).     
 
Cell pelleting experiments.  1x105 UACC257 cells were plated per well in a 6-
well plate.  Cells were treated daily (1x/day) with 4 µM of SIK inhibitor HG 9-91-
01 or vehicle control (30% propylene glycol + 70% ethanol).  After 3 days, cells 
were detached with 0.25% trypsin, resuspended in RPMI media, and 
centrifuged.  RPMI media was removed and pellets were washed 1x with PBS 
and allowed to dry before imaging.  
 
Synthetic procedure of small molecule SIK inhibitors:  
Unless otherwise noted, reagents and solvents were used as received from 
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commercial suppliers. Proton nuclear magnetic resonance spectra were obtained 
on Bruker AVANCE spectrometer at 400 MHz for proton. Spectra are given in 
ppm (δ) and coupling constants, J, are reported in Hertz. The solvent peak was 
used as the reference peak for proton spectra. LC-MS spectra were obtained on 
Agilent 1100 HPLC LC-MS ion trap electrospray ionization (ESI) mass 
spectrometer. 
 
Synthesis of YKL-06-061 (Section written by Jinhua Wang, Dana-Farber 
Cancer Institute) 
All SIK inhibitors were developed in collaboration with the Nathanael Gray 




A mixture of N-((2,4-dichloropyrimidin-5-yl)methyl)-2,6-dimethylaniline (1) (1.10 g, 
3.91 mmol), cyclobutanamine (1.67 g, 23.49 mmol) and DIPEA (6 mL) in THF 
(100 mL) was stirred at room temperature overnight. Then the mixture was 
concentrated, the residue was purified by flash column (eluting with ethyl acetate 
/PE = 0-15%) to give 2-chloro-N-cyclobutyl-5-((2,6-
dimethylphenylamino)methyl)pyrimidin-4-amine (2) as white solid (0.90 g, yield 
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72%). LCMS (m/z): 317 [M + H] +. 
7-chloro-1-cyclobutyl-3-(2,6-dimethylphenyl)-3,4-dihydropyrimido[4,5-
d]pyrimidin-2(1H)-one (3) 
A mixture of 2-chloro-N-cyclobutyl-5-((2,6-dimethylphenylamino)methyl)pyrimidin-
4-amine (2) (0.75 g, 2.37 mmol) and triphosgene (1.05 g, 3.56 mmol) in DCM 
(100 mL) was stirred at room temperature for 1 hour, the a solution of NaOH 
(1.90 g, 47.5 mmol) and n-Bu4NOH (78 mg, 0.301 mmol) in H2O (24 mL) was 
added, the resulting mixture was stirred at room temperature overnight. The 
organic layer was washed with H2O (50 mL × 2), dried with Na2SO4, filtered and 
concentrated, the residue was purified by flash column (eluting with ethyl acetate 
/PE = 0-15%) to give 7-chloro-1-cyclobutyl-3-(2,6-dimethylphenyl)-3,4-
dihydropyrimido[4,5-d] 
pyrimidin-2(1H)-one (3) as white solid (750 mg, yield 92%). LCMS (m/z): 343 [M 
+ H] +. 1H-NMR (CDCl3, 400 MHz): δ 8.11 (s, 1H), 7.11-7.18 (m, 3H), 4.83-4.92 





A mixture of 7-chloro-1-cyclobutyl-3-(2,6-dimethylphenyl)-3,4-
dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (3)  (70 mg, 0.204 mmol), 2-methoxy-
4-(4-methylpiperazin-1-yl)aniline (66 mg, 0.298 mmol) and TFA (0.5 mL) in n-
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BuOH (5 mL) was stirred at 110°C overnight, the mixture was concentrated, the 
residue was purified by prep-HPLC (0.05%NH4HCO3 in CH3CN-H2O) to give 
YKL-06-061 as white solid (50 mg, yield 47%). LCMS (m/z): 528 [M + H] +. 1H-
NMR (CDCl3, 400 MHz): δ 8.22 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.36 (s, 1H), 
7.09 - 7.16 (m, 3H), 6.56 - 6.60 (m, 2H), 4.90 - 4.98 (m, 1H), 4.37 (s, 2H), 3.90 (s, 
3H), 3.20 (t, J = 5.2 Hz, 4H), 2.58 - 2.68 (m, 6H), 2.46-2.54 (m, 2H), 2.38 (s, 3H), 
2.23 (s, 6H), 1.74-1.89 (m, 2H). 
 




A mixture of A mixture of N-((2,4-dichloropyrimidin-5-yl)methyl)-2,6-
dimethylaniline (1) (1.5g, 5.34 mmol), cyclohexanamine (3.17 g, 32.0 mmol) and 
DIPEA (6 mL) was stirred at room temperature overnight. Then the mixture was 
concentrated, the residue was purified by flash column (eluting with ethyl acetate 
/PE = 0-12%) to give 2-chloro-N-cyclohexyl-5-((2,6-
dimethylphenylamino)methyl)pyrimidin-4-amine (4) as white solid (1.5 g, yield 
81%). LCMS (m/z): 345 [M + H] +. 
7-chloro-1-cyclohexyl-3-(2,6-dimethylphenyl)-3,4-dihydropyrimido[4,5-
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d]pyrimidin-2(1H)-one (5) 
A mixture of 2-chloro-N-cyclohexyl-5-((2,6-
dimethylphenylamino)methyl)pyrimidin-4-amine (4) (1.50 g, 4.36 mmol) and 
triphosgene (1.94 g, 6.54 mmol) in DCM (100 mL) was stirred at room 
temperature for 30 minutes, then a solution of NaOH (3.49 g, 87.3 mmol) and n-
Bu4NOH (78 mg, 0.301 mmol) in H2O (43 mL) was added, the resulting mixture 
was stirred at room temperature overnight. The organic layer was washed with 
H2O (50 mL × 2), dried with Na2SO4, filtered and concentrated to give crude 
product, then purified by flash column (eluting with ethyl acetate /PE = 0-20%) to 
give 7-chloro-1-cyclohexyl-3-(2,6-dimethylphenyl)-3,4-dihydro- 
pyrimido[4,5-d]pyrimidin-2(1H)-one (5) as white solid (1.1 g, yield 68%). LCMS 
(m/z): 371 [M + H] +. 
1H-NMR (CDCl3, 400 MHz): δ 8.08 (s, 1H), 7.11-7.18 (m, 3H), 4.63-4.71 (m, 1H), 
4.49 (d, J = 0.8Hz, 2H), 2.45-2.56 (m, 2H), 2.22 (s, 6H), 1.65-1.86 (m, 5H), 1.34-




A mixture of 7-chloro-1-cyclohexyl-3-(2,6-dimethylphenyl)-3,4-
dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (5) (94 mg, 0.254 mmol), 4-(4-
methylpiperazin-1-yl)aniline (97 mg, 0.508 mmol) and TFA (0.5 mL) in n-BuOH (8 
mL) was stirred at 110°C overnight. The mixture was concentrated, the residue 
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was purified by prep-HPLC (0.05%NH4HCO3 in CH3CN-H2O) to give YKL-06-062 
as light yellow solid (94 mg, yield 70%). LCMS (m/z): 526 [M + H] +. 1H-NMR 
(CDCl3, 400 MHz): δ 7.92 (s, 1H), 7.46 - 7.50 (m, 2H），7.09 - 7.15 (m, 3H)，
7.02 (s, 1H), 6.93 - 6.96 (m, 2H), 4.61 - 4.69 (m, 1H), 4.38 (s, 2H), 3.19 (t, J = 5.2 
Hz, 4H), 2.61 (t, J = 5.2 Hz, 4H), 2.43-2.53 (m, 2H), 2.36 (s, 3H), 2.23 (s, 6H), 
1.76 - 1.86 (m, 4H), 1.66 (d, J = 12.4 Hz, 1H), 1.32 - 1.43 (m, 2H), 1.14-1.23 (m, 
1H).  
 
Statistical Analysis.  Data are presented as the mean ± SEM.  
Statistical significance of differences between experimental groups for in vitro 
dose curve experiments were assessed by one-way ANOVA with Dunnett’s 
multiple comparisons post test.  In vitro time course experiments were assessed 
by repeated measures one-way ANOVA with Dunnett’s multiple comparisons 
post test. 
Statistical significance for colorimeter readings in Figure 3B was determined by 
multiple t test analysis between Day 0 and Day 7 for each treatment group, with 
the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli to 
correct for False Discovery Rate (Desired FDR (Q) = 1%) with no assumption of 
consistent SD. 
Statistical significance of differences between experimental groups for in vivo 
time course experiments was assessed by two-way ANOVA analyses with 
Sidak’s multiple comparisons test.   
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Multiplicity adjusted P values were reported for each comparison, and differences 





Small molecule inhibition of SIK induces MITF expression in vitro.    
To test regulation of the pigmentation pathway by the SIK inhibitor HG 9-91-01 
(HG) in vitro, we treated normal human melanocytes, UACC62 human melanoma 
cells, and UACC257 human melanoma cells. Dose-dependent increases in 
expression of MITF were observed in these cells in response to SIK inhibitor 
application (Figure 1A; Figure 2A, 2D). RNA levels of the MITF target gene 
TRPM1 [211] also increased and followed the anticipated delayed kinetics 
relative to MITF induction in normal human melanocytes (Figure 1B, 1C) and 
UACC257 human melanoma cells (Figure 2G, 2H). Gross pigmentation was 
observed in cell pellets of UACC257 human melanoma cells after 3 days of HG 
9-91-01 treatment (Figure 1D).  These data suggest that small molecule SIK 
inhibition can stimulate the pigmentation pathway in vitro.   

































































Figure 2-1: Inhibition of SIK by HG 9-91-01 promotes MITF transcription and pigmentation in vitro.  
(A) mRNA expression of MITF relative to RPL11 mRNA and vehicle control in normal human melanocytes 
3 hours after HG 9-91-01 or vehicle control (70% ethanol; 30% propylene glycol) treatment, quantified by 
qRT-PCR (n=3, mean ± SEM).  mRNA expression of MITF (B) and MITF-dependent gene TRPM1 (C) 
relative to RPL11 mRNA and vehicle control at each time point, in normal human melanocytes over 24 
hours after 4 µM HG 9-91-01 or vehicle control treatment, quantified by qRT-PCR (n=3, mean ± SEM).  (D) 
Cell pellets of UACC257 melanoma cells after 3 days of treatment with vehicle control or 4 µM of SIK 
inhibitor HG 9-91-01 (image is representative of n=3 experiments).  For graph in A, statistical significance 
is reported as follows: ***P < 0.001, ****P < 0.0001, one-way ANOVA with Dunnett’s multiple comparisons 
test comparing treatment dose to vehicle control.  For graphs in B and C statistical significance is reported 
as follows:  *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, repeated measures one-way ANOVA with 
Dunnett’s multiple comparisons test comparing each time point to time point zero.























































































































































































































































































































































Figure 2-2:  Inhibition of SIK by HG 9-91-01, YKL 06-061, and YKL 06-062 in UACC62 and UACC257 
melanoma cells induces MITF expression.  mRNA expression of MITF relative to RPL11 mRNA and 
vehicle control quantified by qRT-PCR in UACC62 melanoma cells (A), (B), (C) and UACC257 melanoma 
cells (D), (E), (F) treated with HG 9-91-01 (A), (D), YKL 06-061 (B), (E), or YKL 06-062 (C), (F) (n=3, mean 
± SEM).  mRNA expression of MITF (G) and MITF-dependent gene TRPM1 (H), relative to RPL11 and 
vehicle control (70% ethanol; 30% propylene glycol) at each time point, in normal human melanocytes 
treated with 4 µM of SIK inhibitor, quantified by qRT-PCR.  For graphs in A-F, statistical significance is 
reported as follows:  *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA with Dunnett’s 
multiple comparisons test comparing treatment dose to vehicle control.  For graphs in G and H, statistical 
significance is reported as follows:  *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, repeated measures 
one-way ANOVA with Dunnett’s multiple comparisons test comparing each time point to time point zero.
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HG 9-91-01 rescues melanogenesis in mice with inactive melanocortin 1 
receptor.    
Since our in vitro results demonstrated that inhibition of SIK by HG 9-91-01 
positively regulated MITF transcription, we next evaluated whether topical 
application of this compound could induce pigmentation independent of Mc1r in 
vivo.  To test this, we utilized a previously described mouse “red hair” model 
which carries the inactivating Mc1re/e mutant allele and a transgene, K14-SCF, in 
which Stem Cell Factor expression is driven by the Keratin-14 promoter, allowing 
for epidermal homing of melanocytes [1, 339].  Albino mice harboring a mutation 
in the tyrosinase gene were combined with the K14-Scf transgene (Tyrc/c;K14-Scf 
mice) and served as controls to evaluate whether the pigmentation afforded by 
topical SIK inhibitor was dependent upon the canonical tyrosinase-melanin 
pathway.  Daily application of the SIK inhibitor HG 9-91-01 for 7 days caused 
robust darkening in Mc1re/e;K14-Scf mice (Figure 3A; 5A).  No visible change in 
skin pigmentation was observed in Mc1re/e;K14-Scf mice treated with vehicle or 
Tyrc/c;K14-Scf mice treated with vehicle or HG 9-91-01 (Figure 3A; 5A; 
5B).  Reflective colorimetry analysis (Commission Internationale de l’Eclairage 
[CIE] L* white-black color axis [340] revealed significant darkening in 
Mc1re/e;K14-Scf mice treated with SIK inhibitor, but not in vehicle treated 
Mc1re/e;K14-Scf mice or Tyrc/c;K14-Scf mice treated with either SIK inhibitor or 
vehicle control (70% ethanol; 30% propylene glycol) (Figure 3B).  Fontana-
Masson staining, a specialized melanin stain, revealed strong induction of 
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melanin production in Mc1re/e;K14-Scf mice only in areas treated with HG 9-91-
01 (Figure 3C; 5D), but no pigment induction in Mc1re/e;K14-Scf mice treated 
with vehicle (Figure 3C) or in albino (Tyrc/c;K14-Scf) mice treated with either 
vehicle or SIK inhibitor (Figure 5C).  Nuclear capping of melanin-laden 
melanosomes was observed within epidermal keratinocytes in Mc1re/e;K14-Scf 
mice treated with HG 9-91-01 (indicated by white arrows) and represents a 
known subcellular localization typical of physiologic skin pigmentation [341] 
(Figure 3C).  This feature suggests that SIK inhibitor treatment not only 
stimulates melanocytic pigment synthesis, but also the export of melanin in a 
fashion that closely mimics the known pathway of UV melanogenesis. 
Hematoxylin and eosin staining revealed normal morphology of HG 9-91-01 
treated Mc1re/e;K14-Scf (Figure 3C) and Tyrc/c;K14-Scf epidermis (Figure 5C). 
Additionally, NaOH lysis of skin samples [342] revealed a visible increase in 
extractable eumelanin from Mc1re/e;K14-Scf mice treated with HG 9-91-01 
compared to all other treatment groups (Figure 3D).  The darkening induced by 
topical application of HG 9-91-01 to Mc1re/e;K14-Scf mice was progressive over 6 
days of treatment and reversible around 2 weeks after treatment was stopped 
(Figure 4A; 4B).  Skin pigmentation remained in its pretreatment state 26 days 
later (40 days after treatment ended) (Figure 4A; 4B).  No change was observed 
in Tyrc/c;K14-Scf mice during treatment or 14 days after treatment was stopped 
(Figure 4C).  Forty days after treatment was stopped, Fontana-Masson staining 
of skin sections of Mc1re/e;K14-SCF mice and Tyrc/c;K14-SCF mice revealed no 
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differences between vehicle and treatment groups, and hematoxylin and eosin 
staining illustrated normal morphology for all mice (Figure 5E).  These findings 
combined with the small molecule and lipophilic nature of the SIK inhibitors led 


































































































Figure 2-3:  Topical treatment with HG9-91-01 causes robust darkening in MC1Re/e;K14-Scf 
mice.  (A)  MC1Re/e;K14-Scf mice and Tyrc/c;K14-Scf mice before treatment (Day 0) and after 7 days of 
treatment (Day 7) with 30 uL of vehicle control (70% ethanol; 30% propylene glycol) or 37.5 mM HG 
9-91-01 (image is representative of n=4 experiments).  Reflective colorimetry measurements (L* white-
black color axis) (n=4, mean ± SEM)  (B) and melanin extraction (image is representative of n=4 
experiments) (D)  of MC1Re/e;K14-Scf mice and Tyrc/c;K14-Scf mice described in A .  (C) Fontana-
Masson (eumelanin) [top two panels]  and hematoxylin and eosin [bottom two panels] stained skin 
sections of MC1Re/e;K14-Scf mice (x400 magnification), white arrows represent nuclear capping, (image 
is representative of n=4 experiments) of  MC1Re/e;K14-Scf mice described in A. For the graph in B, 
statistical significance is reported as follows: ****P < 0.0001, multiple t test analysis with two-stage linear 
step-up procedure of Benjamini, Krieger and Yekutieli.
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Figure 2-4:  Darkening induced by topical application of HG 9-91-01 to MC1Re/e;K14-Scf mice is 
progressive and reversible.  (A) MC1Re/e;K14-Scf mice and Tyrc/c;K14-Scf mice after treatment with 30 uL 
of vehicle control (70% ethanol; 30% propylene glycol) or 37.5 mM HG 9-91-01:  before treatment (Day 0) 
and after 6 days of treatment (Day 6), and 40 days post-treatment (Day 46) (vehicle mouse in Day 46 photo 
is different from Day 0 and Day 6 photo).  Reflective colorimetry measurements (CIE L* white-black color 
axis) of MC1Re/e;K14-Scf mice (B) and Tyrc/c;K14-Scf mice (C) described in A (Tyrc/c;K14-Scf mice vehicle: 
n=3 (Day 0-10), n=2 (Day 11-20); Tyrc/c;K14-Scf mice HG 9-91-01: n=3; MC1Re/e;K14-Scf mice vehicle: n=5 
(Day 0-19), n=4 (Day 24-34); MC1Re/e;K14-Scf mice HG 9-91-01: n=3 mean ± SEM).  For all graphs, 
statistical significance is reported as follows:  *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way 
ANOVA with Sidak’s multiple comparisons test comparing treatment to vehicle control at each time point.  





































































































































Figure 2-5:  Expansion of in vivo experiments.  Mc1re/e;K14-SCF mice (A) and Tyrc/c;K14-SCF mice (B) 
before treatment (Day 0) and after 7 days of treatment (Day 7) with 30 µL of vehicle control (70% ethanol; 
30% propylene glycol) or 37.5 mM HG 9-91-01 (image of all replicates of mice represented in Figure 
3A).  (C) Fontana-Masson (eumelanin) [top panel] and hematoxylin and eosin stains [bottom panel] of 
Tyrc/c;K14-SCF mice as described in Figure 3A  (x630 magnification) (image is representative of n=4 
experiments).  (D) Fontana-Masson (eumelanin) stained skin sections of Mc1re/e;K14-SCF mice treated 
with 37.5 mM HG 9-91-01 for 7 days as described in Figure 3A.   Image is at the margin of treated and 
untreated area (x100 magnification). (E) Fontana-Masson (eumelanin) [left panels] and hematoxylin and 
eosin stains [right panels] of Mc1Re/e;K14-SCF mice and Tyrc/c;K14-SCF mice with vehicle or 37.5 mM HG 
9-91-01 as described Figure 4A (x200 magnification).
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Second generation SIK inhibitors are as efficacious in inducing the 
pigmentation pathway as HG 9-91-01.  
Since there are limitations to topical delivery of HG 9-91-01 into human skin 
epidermis (Figure 8A-8D), we designed novel SIK inhibitors with the aim of 
enhancing epidermal permeation by optimizing size and lipophilicity (cLogP), and 
developed second generation SIK inhibitors YKL 06-061 and YKL 06-062 
(Figure 6D) [343, 344]. Second generation inhibitors had comparable IC50 
values for inhibition of SIK1, SIK2, and SIK3 as HG 9-91-01 (Figure 6A). To 
assess the kinome selectivity information of new analogs, YKL-06-061 was 
screened across a panel of 468 human kinases at a concentration of 1 µM using 
the KinomeScan methodology (DiscoverX).  YKL-06-061 exhibited an S(1) score 
of 0.02, with 16 kinases displaying tight binding to it (Ambit scores of ≤1) (Figure 
6B). As the KinomeScan assays measure binding, we also performed enzymatic 
assays for these targets either in-house or using the SelectScreen Kinase 
Profiling Service at Thermo Fisher Scientific (Madison, WI) (Figure 6C). YKL-06-
061 inhibited only one kinase, fyn-related kinase (FRK), more strongly than SIKs, 
which demonstrates its high overall selectivity (Figure 6C). We anticipate that 
YKL-06-062 has similar kinase selectivity, considering their high structural 
similarity.  Similar to observations with HG 9-91-01, treatment of normal human 
melanocytes (Figure 7A; 7B), UACC62 human melanoma cells (Figure 2B; 2C), 
and UACC257 human melanoma cells (Figure 2E; 2F) with YKL 06-061 or YKL 
06-062 for 3 hours yielded a dose dependent increase in MITF mRNA 
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expression. Levels of TRPM1 mRNA increased after MITF induction upon 
treatment with YKL 06-061 or YKL 06-062 in normal human melanocytes and 
UACC257 human melanoma cells (Figure 7C; 7D; Figure 2G; 2H). 
	  	   	  
63	  
 	  	  
A
B C
D Molecule Name 
Molecular 
weight 










Figure 2-6: Characterization of SIK inhibitors.  (A) Structures of HG-9-91-01, YKL-06-061, and 
YKL-06-062, and their biochemical IC50s against SIKs.   (B) KinomeScan kinase selectivity profile for 
YKL-06-061. YKL-06-061 was profiled at a concentration of 1 µM against a diverse panel of 468 kinases 
by DiscoverX.  Kinases that exhibited a score of 1 or below are marked in red circles (Score is percent 
relative to DMSO control. Smaller numbers indicate stronger binding).  (C) Biochemical kinase IC50s of 
YKL-06-061 top hits as shown in B.  (D) Physiochemical properties of first- and second-generation SIK 
inhibitors.  TK: Tyrosine kinase;  TKL: Tyrosine kinase-like;  STE: Homologs of yeast Sterile 7, Sterile 11, 
Sterile 20 kinases;  CK1: Casein kinase 1;  AGC: Containing PKA, PKG, PKC families; CAMK: Calcium/
calmodulin-dependent protein kinase; CMGC: Containing CDK, MAPK, GSK3, CLK families. (Figure by 
Yanke Liang and Jinhua Wang, Dana-Farber Cancer Institute).
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Figure 2-7:  Second generation SIK inhibitors are as efficacious in inducing the pigmentation 
pathway as HG 9-91-01.  mRNA expression of MITF relative to RPL11 mRNA and vehicle control in 
normal human melanocytes, treated with YKL 06-061 (A), YKL 06-062 (B), or vehicle control (70% 
ethanol; 30% propylene glycol) (A,B), quantified by qRT-PCR (n=3, mean ± SEM).  mRNA expression of 
MITF (C) and MITF-dependent gene TRPM1 (D) relative to RPL11 and vehicle control at each time 
point, in normal human melanocytes over 24 hours after 4 µM YKL 06-061, YKL 06-062, or vehicle 
control treatment, quantified by qRT-PCR.  For graphs in A and B, statistical significance is reported as 
follows:  ***P < 0.001, ****P < 0.0001, one-way ANOVA with Dunnett’s multiple comparisons test 
comparing treatment dose to vehicle control.  For graphs in C and D, statistical significance is reported 
as follows:  *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, repeated measures one-way ANOVA with 
Dunnett’s multiple comparisons test comparing each time point to time point zero.


































































* **** ** ****
*
	  	   	  
65	  
Topical SIK inhibitors induce human skin eumelanization.   
Treatment of human skin explants with passive topical application of the second 
generation SIK inhibitors, YKL 06-061 and YKL 06-062, induced significant 
pigmentation after 8 days of treatment (1x/day), but no significant gross 
pigmentation was observed in skin treated with HG 9-91-01 (Figure 8A). 
Fontana Masson staining revealed increased melanin content in skin treated with 
YKL 06-061 or YKL 06-062, and marginally increased melanin in skin treated 
with HG 9-91-01, as compared with control (Figure 8B). This effect was 
reproducible with independent preparations of synthesized drugs applied 
passively (via pipette) to the top of different human skin explants (Figure 8C; 
8D). Mechanical application of the first generation SIK inhibitor HG 9-91-01, by 
rubbing via an applicator, induced significant gross pigmentation (Figure 8E), 
and increased melanin content was observed upon Fontana Masson staining of 
skin sections (Figure 8F), suggesting HG 9-91-01’s limited human skin 
penetration can be at least partially overcome through mechanical application.  
YKL 06-061 and YKL 06-062 did not require mechanical application (rubbing) to 
induce significant human epidermal darkening. 	  


































































































































Figure 2-8: Treatment of human skin explants with 37.5 mM of SIK inhibitor induces 
pigmentation.  (A) Human breast skin explants treated with passive application of vehicle control (70% 
ethanol; 30% propylene glycol) or 37.5 mM of SIK inhibitor YKL 06-061, YKL 06-062, or HG 9-91-01 for 8 
days (10 µL; 1x/day).  Image taken 2 days after end of treatment. (image is representative of two of n=3 
experiments)). (B) Fontana-masson (top panel) and hematoxylin and eosin (bottom panel) staining (x400 
magnification) of breast skin described in A. (C) Human breast skin explants treated with passive 
application of vehicle control or 37.5 mM of SIK inhibitor YKL 06-061, YKL 06-062, or HG 9-91-01 for 5 
days  (10 µL; 2x/day).  Image taken 1 day after end of treatment  (image is representative of n=1 
experiments).  (D) Human breast skin explants treated with passive application of vehicle control or 37.5 
mM of SIK inhibitor YKL 06-061, YKL 06-062, or HG 9-91-01 for 6 days  (10 µL; 2x/day).  Image taken 1 
day after end of treatment  (image is representative of n=1 experiment) . (E)  Human breast skin explants 
treated with mechanical application of vehicle control or 50 mM (50 µL for 1 day; 1x/day) or 25 mM (50 µL 
for 3 days; 3x/day) of HG 9-91-01.  Image taken 4 days after start of treatment (image is representative of 
n=1 experiment) .  (F) Fontana-masson (top panel) and hematoxylin and eosin (bottom panel) staining 
(x400 magnification) of human skin explants described in E.
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DISCUSSION  
These results illustrate the development and successful application of small 
molecule SIK inhibitors for topical induction of skin pigmentation independently of 
UV irradiation in human skin. SIK inhibitors were shown to induce enhanced 
expression of the MITF transcription factor, which is known to regulate 
expression of numerous pigment enzymes that promote biosynthesis of 
eumelanin. A new generation of SIK inhibitors was developed, based on 
strategies for enhancing the likelihood of skin penetration through optimizing 
molecular size and lipophilicity. Two such SIK targeted inhibitors, YKL 06-061 
and YKL 06-062, were shown to induce similar responses both in vitro and when 
applied to human skin explants. In addition to upregulating mRNA levels of MITF 
and TRPM1, topical SIK inhibitors were seen to trigger transfer of melanosomes 
into epidermal keratinocytes in a manner that recapitulates the perinuclear 
capping (subcellular localization) seen in normal human epidermal pigmentation. 
Thus, SIK inhibitor treatments appear to induce not only synthesis of melanin, but 
also melanosomal maturation, export, and localization features, even after import 
into keratinocytes. These features closely resemble the previously observed 
behavior of forskolin treatment in red-haired mice [1]. 
The application of topical small molecule UV-independent pigment inducers has 
not yet been examined in humans and would require careful considerations of 
safety. For example, the induction of dark pigmentation is associated with the 
lowest risk of most skin cancers in man [20, 335], and this pigment synthesis is 
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believed to be dependent upon MITF [162]. Yet fixed genomic mutation or 
amplification of the MITF gene can be oncogenic in certain contexts [2, 345, 
346]. Reversible upregulation of MITF as reported here is also likely to occur in 
routine instances of UV-tanning, and constitutive elevation of MITF is likely in 
skin of individuals with darker pigmentation levels; neither would be anticipated to 
trigger genomic mutation of the MITF gene. Analogously, transient administration 
of recombinant hematopoietic growth factors has not been associated with 
formation of oncogenic transformation or leukemia [347, 348]. In mice, topical 
forskolin’s pigmentary rescue in “redheads” resulted in significant protection from 
UV carcinogenesis, without apparent associated toxicities over many months of 
treatment [1]. A recent study has utilized injections of the synthetic α-MSH 
analogue, afamelanotide, for treatment of photosensitivity associated with 
erythropoietic protoporphyria.  Pigmented lesions/melanoma were carefully 
evaluated and reported not to occur at elevated risk [349].  
The half-life of melanin in skin is thought to be several weeks and diminishes 
primarily after superficial keratinocyte sloughing. Most epidermal melanin resides 
within keratinocytes after transfer of melanosomes from melanocytes. Therefore, 
it is possible that small molecule approaches like that described here might be 
achievable, or maintained, through intermittent dosing strategies. In conclusion, 
these studies describe a small molecule topical approach to the rescue of 
eumelanin synthesis in a UV-independent manner. Future studies will be needed 
to examine the optimal applications of such agents in a variety of clinical settings. 
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Over the past decades, the incidence of melanoma has risen in the United States 
[40, 41].  More than 80% of malignant melanomas harbor a BRAF (V600E) or 
NRAS (Q61R) mutation [61-63, 350].  These proto-oncogenes regulate the 
mitogen-activated protein kinase (MAPK) pathway, a signaling pathway which 
regulates multiple cancer-associated phenotypes  [68, 75, 351].  MITF, an 
oncogene amplified in 10%-20% of melanomas [2, 225], confers resistance to 
BRAF and MEK inhibitors [187, 226, 227].  Furthermore, BRAF (V600E) 
cooperates with MITF upregulation  to establish tumorigenic programming in 
human melanocytes [2], yet melanomas with aberrant activation of the MAP 
kinase pathway show suppression of MITF [6].  To understand melanomagenic 
transformation of melanocytes and to target resistance of MAPK inhibitors, a 
greater understanding is needed of how BRAF (V600E) and NRAS (Q61R) 
mutant tumors recover MITF. 
During normal ultraviolet-induced tanning, activation of the α-MSH signaling 
pathway leads to an increase in the second messenger cAMP signaling, 
amplification of protein kinase A (PKA) signaling, and phosphorylation/activation 
of the MITF transcriptional regulator cAMP response element binding protein 
(CREB) [1, 159, 160].  Independent of CREB phosphorylation by PKA, CREB 
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regulated transcription coactivator (CRTC) can bind and activate CREB to induce 
MITF expression [238].  The AMPK-related kinase salt inducible kinase (SIK) 
serves as an upstream negative regulator of CRTC-CREB-MITF signaling by 
phosphorylating CRTC and preventing nuclear translocation of CRTC [238, 240].   
Autosomal dominant mutation of the tumor suppressor liver kinase B1 (LKB1), 
also known as serine-threonine kinase 11 (STK11), leads to Peutz-Jegher 
syndrome, characterized  by mucocutaneous hyperpigmentation, hamartomas, 
and increased risk of malignancy [352-354].  Moreover, LKB1 is a master 
regulator of the activity of AMPK and 12 AMPK-related kinases including SIK 
[237], and LKB1 can regulate CRTC-CREB activity through activating SIK [240].  
We hypothesized that LKB1 regulates the SIK-CRTC-MITF axis and aberrations 
in LKB1/SIK levels lead to MITF augmentation in MAP kinase pathway mutated 
melanomas.  
 
Materials and Methods 
Visualization of Cancer Genomic Alterations.  Genomic data from 471 skin 
cutaneous melanoma tumors from The Cancer Genome Atlas Analysis (TCGA) 
was analyzed using cBioPortal for Cancer Genomics [4, 5].  Mutations, putative 
copy-number alterations from GISTIC, mRNA expression z-scores (RNA seq V2 
RSEM) with a z-score threshold of 2, and protein expression z-scores (RPPA) 
with a z-score threshold of 2 were selected for genomic profile analysis.    
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Cell Lines:  G361, A2058, SKMEL5, MEWO cells were obtained from the 
American Type Culture Collection (ATCC).  UACC62 and UACC257 cells were 
obtained from the National Cancer Institute (Federick, MD) DTP, DCTD cell 
line/tumor repository.   
 
Cell Culture.  Human melanoma cells were grown in either RPMI or DMEM 
medium + 1% penicillin/streptomycin/glutamine + 5% fetal bovine serum. Normal 
human melanocytes were grown in TIVA medium (HAM’s F-12, 1% 
penicillin/streptomycin/glutamine, 10% fetal bovine serum, 50ng/mL 12-O-
tetradecanoyl phorbol-13-acetate, 1 x 10-4 M 3-isobutyl-1-methyl xanthine, 1 µM 
Na3VO4, 1 x 10−3 M N6,2’-O-dibutyryladenosine 3:5-cyclic monophosphate), and 
were starved for 24 hours in HAM’s F-12 + 1% penicillin/streptomycin/glutamine 
before all molecular experiments.  For more information see Table 1 h 
[355, 356]. 




Table 3-1:  Cell lines used in this study.  Species of origin, tissue of origin, disease, metastatic site (if 







293$T$Cells Human Embryonic$Kidney Not$Applicable$ Not$Applicable$ Unknown DMEM
451LU Human Skin Malignant$Melanoma Lymph$Node Male DMEM
501MEL Human Skin Malignant$Melanoma Unknown Female DMEM
A101D Human Skin Malignant$Melanoma Unknown Male DMEM
A2058 Human Skin Amelanotic$Malignant$Melanoma Lymph$Node Male DMEM
A375 Human Skin Amelanotic$Malignant$Melanoma Unknown Female DMEM
A375p Human Skin Amelanotic$Malignant$Melanoma Unknown Female DMEM
C32 Human Skin Amelanotic$Malignant$Melanoma Unknown Male DMEM
COLO792 Human Skin Malignant$Melanoma Brain Male DMEM
COLO800 Human Skin Malignant$Melanoma Subcutaneous$ Male DMEM
COLO829 Human Skin Malignant$Melanoma Unknown Male DMEM
G361 Human Skin Malignant$Melanoma Unknown Male DMEM
IPC298 Human Skin Cutaneous$Melanoma Not$Applicable$ Female DMEM
ISTRMEL1 Human Skin Malignant$Melanoma Unknown Male DMEM
KO29S Human Skin Malignant$Melanoma Unknown Unknown DMEM
L3MEL Human Skin Malignant$Melanoma Unknown Unknown DMEM
LBR373RMELD Human Skin Malignant$Melanoma Unknown Unknown DMEM
M14 Human Skin Amelanotic$Malignant$Melanoma Subcutaneous Male DMEM
M2RMEL Human Skin Malignant$Melanoma Unknown Unknown DMEM
MALMER3M Human Skin Malignant$Melanoma Lung Male DMEM
MDARMBR435 Human Skin Amelanotic$Malignant$Melanoma Subcutaneous$ Male DMEM
MELRHO Human Skin Malignant$Melanoma Unknown Female DMEM
MELRJUSO Human Skin Cutaneous$Melanoma Not$Applicable$ Female DMEM
MEWO Human Skin Malignant$Melanoma Lymph$Node Male DMEM
Normal$Human$Melanocytes Human Skin Not$Applicable$ Not$Applicable$ Unknown TIVA
RPMI7951 Human Skin Malignant$Melanoma Lymph$Node Female DMEM
RVH421 Human Skin Malignant$Melanoma Unknown Male DMEM
SKMEL119 Human Skin Cutaneous$Melanoma Not$Applicable$ Unknown DMEM
SKMEL187 Human Skin Malignant$Melanoma Unknown Unknown DMEM
SKMEL2 Human Skin Malignant$Melanoma Remote$Skin$Site$ Male DMEM
SKMEL24 Human Skin Malignant$Melanoma Lymph$Node Male DMEM
SKMEL28 Human Skin Cutaneous$Melanoma Not$Applicable$ Male DMEM
SKMEL3 Human Skin Malignant$Melanoma Lymph$Node Female DMEM
SKMEL30 Human Skin Cutaneous$Melanoma Not$Applicable$ Male DMEM
SKMEL5 Human Skin Malignant$Melanoma Lymph$Node Female DMEM
SKMEL90 Human Skin Malignant$Melanoma Unknown Unknown DMEM
UACC257 Human Skin Malignant$Melanoma Unknown Unknown RPMI
UACC62 Human Skin Malignant$Melanoma Unknown Unknown RPMI
VM10 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM112 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM115 Human Skin Malignant$Melanoma Unknown Female DMEM
WM1575 Human Skin Malignant$Melanoma Unknown Male DMEM
WM1716 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM1745 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM198 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM3314 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM3457 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM3526 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM3862 Human Skin Malignant$Melanoma Unknown Unknown DMEM
WM88 Human Skin Malignant$Melanoma Unknown Male DMEM
WM94 Human Skin Malignant$Melanoma Unknown Unknown DMEM
YUAC2 Human Skin Malignant$Melanoma Unknown Unknown DMEM
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Quantitative real time polymerase chain reaction (qRT-PCR).  mRNA was 
extracted from cells using the RNeasy Mini Kit (Qiagen).  KAPA SYBR ® FAST 
Universal One-Step qRT-PCR Kit (KAPA BIOSYSTEMS) was used to prepare 
mRNA samples for qRT-PCR and samples were analyzed using the 7500 Fast 
Real Time PCR System (Applied Biosystems).  The relative expression of each 
gene was calculated by 7500 Fast System Software, which utilizes Ct normalized 
to mRNA levels of RPL11 to calculate relative expression.  Results are reported 
relative to control cells.  Primer sequences used:  human M-specific MITF 
forward 5’-CATTGTTATGCTGGAAATGCTAGAA-3’, human M-specific MITF 
reverse 5’-GGCTTGCTGTATGTGGTACTTGG-3’, RPL11 forward 5’- 
GTTGGGGAGAGTGGAGACAG-3’, RPL11 reverse 5’-
TGCCAAAGGATCTGACAGTG-3’. Human LKB1.1 forward 5’-
GCCGTCAAGATCCTCAAGAA-3’, human LKB1.1 reverse 5’-
TTTTTGTGCCGTAACCTCCT-3’,  
 
Western blot analysis.  Cells were washed three time with phosphate-buffered 
saline (PBS).  Cells were lysed on ice for 30 minutes with cold RIPA Buffer 
(Sigma-Aldrich) (containing 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease inhibitor 
[cOmplete protease inhibitor cocktail (Sigma-Aldrich)].  Plastic cell lifters were 
used to scrape cells vigorously and cells lysates were placed into a 
microcentrifuge tube and spun at 10,000 RPM at 4oC for 10 minutes.  If not used 
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immediately, cell lysates were stored at -20oC.  Protein quantification was 
conducted using Pierce™ BCA Protein Assay Kit with bovine serum albumin 
serial dilutions for standard curve.   15 uL of sample was run on 4-20% 
Criterion™ TGX™ Precast Gels - Bio-Rad and run at 75 mA at A constant for 50-
60 minutes.  Proteins were transferred to nitrocellous membranes 1 hour at 110 
volts.  After transfer, membranes were blocked for 1 hour in 5% milk  tris-buffered 
saline + tween (TBS-T).  Then were incubated overnight in primary antibody in 
5% milk-TBST solution at 4oC.  Membranes were washed 3x in TBS-T for 15 
minutes, and then incubated in horseradish peroxidase (HRP) bound secondary 
antibody -5% BSA-TBST solution for 1 hour.  Membranes were washed 3x in 
TBS-T for 15 minutes and HRP was detected by incubating membrane in 
Western Lightning™ Chemiluminescence Reagent Plus for 30 seconds – 1 
minute and was exposed to X-ray film to visualize luminescence.   
 
Antibodies.  Primary antibodies:  LKB1 (27D10) (1:1000) and SIK2 (D28G3) 
(1:1000) antibodies were obtained from Cell Signaling Technology; polyclonal 
SIK1 (1:1000), Tubulin (DM1A) (1:20,000), and β-actin (AC-15) (1:20,000) 
antibodies were obtained from Sigma Aldrich; MITF (C5) hybridoma supernatant 
(1:20). 
 
Lentivirus Plasmids.  DNA insert was cloned into the pLenti CMV Hygro DEST 
(w117-1) (Plasmid #17454) using a restriction enzyme cloning method. 
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Lentivirus generation.  (Day 1) 1 x 106 293 T-cells were plated in each well of a 
6-well plate in DMEM medium + 1% penicillin/streptomycin/glutamine + 5% fetal 
bovine serum.  (Day 2) 1250 ng of pLenti-DNA insert, 250 ng lentiviral packaging 
system VSV-G (Cell Biolabs Inc), and 1250 ng psPAX2 (Addgene) were mixed 
and left at room temperature for 15 minutes and were then added to plated 293 T 
cells.  (Day 3) Media was changed to 3 mL of DMEM medium + 30% fetal bovine 
serum.  (Day 4) Supernatant was collected and new 3 mL of DMEM medium + 
30% fetal bovine serum was added to plate.  (Day 5) Supernatant was collected 
and all 6 mL of collected supernatant was filtered using a 0.45 uM filter and were 
stored at 4oC. 
 
 
Melanoma and Melanocyte Lentiviral Transduction.  (Day 1) 1 x 106 
melanoma cells were plated in each well of a 6-well plate. (Day 2) Virus and 2 uL 
of polybrene infection reagent were added to plated cells and plates.  Plates 
were spun at room temperature for 1.5 hours at 1,000 RPM.  (Day 3)  Media was 
changed. (Day 4) Only for melanocytes media was changed to factor free HAM’s 
F-12 + 1% penicillin/streptomycin/glutamine before (Day 5) Protein and mRNA 
samples were collected.   
For experiments with SIKi addition, all steps were as described above, but on 
Day 5 cells were incubated in 1uM of SIKi or vehicle control (DMSO) and mRNA 
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and protein samples were collected 3 hours and 6 hours, respectively, after 
incubation. 
 
Small interfering RNA transfection.  (Day 1) 1 x 106 melanoma cells were 
plated in each well of a 6-well plate. (Day 2) 99 uL of 2.5 mM NaOAc, siRNA, and 
1 uL of lipidoid were mixed, vortexed, and let stand at room temperature for 15 
minutes.  Media in 6-well plate was changed to 900 uL/well and mixture was 
added to media. (Day 3) Media was changed.  (Day 4) mRNA was extracted. 
 
Small interfering RNAs.  Small interfering RNAs for LKB1 and CRTC2 were 
obtained from GE Dharmacon. 
 
Cell Viability Assay.  Cell viability assay was conducted according to protocol 
supplied by manufacturer for CellTiter-Glo® Cell Viability Assay. 
 
Statistical analysis.  Data was analyzed using Prism 6.0 (GraphPad).  Data are 
presented as the mean ± SEM.  For WM88 LKB1 knockdown experiment, 
unpaired two-tailed T test with Welch’s correction was conducted.  For LKB1 
overexpression experiment with and without SIK inhibitor treatment one-way 
ANOVA with Dunnett’s multiple comparisons test compared to control vector.  
For SIK inhibitor on cell viability experiment, one-way ANOVA with Dunnett’s 
multiple comparisons test compared to vehicle control was used.  For small 
	  	   	  
77	  
hairpin knockdown plus NRAS (Q61R) expression in melanocyte experiment, 
one-way ANOVA with Dunnett’s multiple comparisons test compared to 
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RESULTS 
Alterations in LKB1-SIK-CRTC-CREB-MITF pathway in melanoma.  
Analysis of The Cancer Genome Atlas (TCGA) utilizing the cBioPortal for Cancer 
Genomics revealed alterations in the LKB1-SIK-CRTC-MITF pathway in 49% of 
skin cutaneous melanoma samples [4, 5] (Figure 1).  Next, we examined mRNA 
expression of LKB1 (Figure 2A) and protein levels of LKB1, SIK1, SIK2 and 
MITF (Figure 2B-2C) in multiple melanoma cell lines.  Reduced LKB1 mRNA 
expression and protein level were observed in majority of melanoma cell lines 
evaluated compared to normal human melanocytes (Figure 2B-2C).  Decreased 
SIK2 protein levels and SIK1 protein levels were also observed in melanoma 
cells compared to normal human melanocytes (Figure 2C).  No clear correlation 
was discernable between LKB1 or SIK protein levels and MITF. 
 
	  	   	  
79	  
  	  
   
Figure 3-1:  Collectively, LKB1, SIK, CRTC, MITF are altered in 49% of the 471 skin cutaneous 
melanomas from The Cancer Genome Atlas (TCGA) dataset.  Alterations including genomic 
amplifications, deep deletions, mRNA downregulation, mRNA upregulation, protein upregulation, protein 
downregulation, truncating mutations, inframe mutations, and missense mutations in LKB1, SIK1, SIK2, 
SIK3, CRTC1, CRTC2, CRTC3, and MITF  in skin cutaneous melanomas in the The Cancer Genome 
Atlas database (n=471).  



































































































   
   
   
   
   






































































































































































































































































































































































































Figure 3-2:  Human melanoma cells have altered LKB1, SIK1, SIK2, and MITF levels. (A) 
Ectopic mRNA expression of LKB1 relative to RPL11 and normal human melanocytes in normal 
human melanocytes, human melanoma cell lines, and 293 T cells quantified by qRT-PCR (n=1).  
(B) Western blot analysis of LKB1 and MITF protein levels in normal human melanocytes, human 
melanoma cells, and 293 T cells (n=1).  (C)  Western blot analysis of LKB1, SIK1, SIK2 and MITF 
protein levels in normal human melanocytes, human melanoma cells, and 293 T cells (n=1).  
(Figure 2C was contributed by Akinori Kawakami)  
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LKB1 regulates localization of CRTC2. 
Since LKB1 is a known SIK inducer and SIK regulates CRTC2 nuclear 
translocation, we next investigated LKB1’s effects on CRTC2 localization in vitro 
[3, 238].  To evaluate regulation of nuclear localization of CRTC2 by LKB1, 
LKB1-deficient G361 melanoma cells were infected with lentivirus expressing 
CRTC2 tagged with green fluorescent protein (CRTC2-GFP) with concurrent viral 
transduction with LKB1 (WT) overexpressing vector or empty vector.  Moreover, 
immortalized human melanocytes (pmel*) with p53 inactivation, CDK4(R24C) 
and telomerase (hTERT) expression [2] were transfected with pooled si-
Scramble or pooled siLKB1. Preliminary experiments show that LKB1 
overexpression enhanced cytoplasmic localization of CRTC2-GFP in G361 
melanoma cells (Figure 3A).  Knockdown of LKB1 in pmel* cells increased 
nuclear translocation of CRTC2-GFP (Figure 3B).  Moreover, CRTC2 
knockdown decreased MITF protein level in WM1968 melanoma cells (Figure 
3C) suggesting that LKB1 could regulate MITF expression through modulation of 
CRTC2 localization. 
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Figure 3-3:  Wildtype LKB1 overexpression inhibits CRTC2-GFP nuclear localization, and 
knockdown of LKB1 increases nuclear import of CRTC-GFP. (A) Overexpression of CRTC2-GFP in 
G361 melanoma cells with control vector or wildtype LKB1 (WT) overexpression (x200 magnification) 
(n=1).  (B) CRTC-GFP overexpression in pmel* cells transfected with control si-Scramble or siLKB1 (x200 
magnification) (n=1). (C)  Western blot analysis of CRTC2 and MITF of WM1968 melanoma cells 
expressing short hairpins RNAs (shRNAs) targeting CRTC2 (CRTC2sh1 and CRTC2sh2) or a control 
shRNA targeting the luciferase transcript (shLuc) (n=1). (Figure 3C was contributed by Ryo Murakami)





LKB1 and SIK regulate MITF expression in melanoma cell lines 
Since our results demonstrated that LKB1 negatively regulates CRTC2 nuclear 
localization and CRTC2 knockdown decreases MITF protein levels in melanoma 
cells, we next evaluated whether LKB1 overexpression in LKB1-deficient G361 
melanoma cells or LKB1-deficient A2058 melanoma cells could decrease mRNA 
expression and protein level of MITF.  Titrated overexpression of LKB1 in G361 
melanoma cells (Figure 4A) and A2058 melanoma cells (Figure 4B) illustrates a 
dose dependent effect on suppression of MITF mRNA expression (Figure 4C; 
4D) and MITF protein level (Figure 4E; 4F), but no change in MITF mRNA 
expression is seen when kinase defective LKB1 (D194A) is overexpressed in 
G361 melanoma cells (Figure 4G; 4H).  Overexpression of LKB1 in SKMEL5 
melanoma cells, UACC62 melanoma cells, and SKEML90 melanoma cells 
decreases MITF protein levels (Figure 4I).  Knockdown of LKB1 by siRNA in 
WM88 melanoma cells (Figure 4J) induced a 2-fold increase of MITF mRNA 
expression (Figure 4K).  Titrated overexpression of wildtype SIK2 suppresses 
MITF protein level in MeWo melanoma cells, but there is no change in MITF after 
overexpression of kinase defective SIK2 (K49M) (Figure 4L).  Inhibition of SIK by 
the selective SIK inhibitor HG 9-91-01 [338] rescued MITF mRNA expression 
(Figure 5A-5D) and  protein level (Figure 5E) suppressed by LKB1 
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overexpression in G361 melanoma cells (Figure 5A; 5C; 5E) and A2058 
melanoma cells (Figure 5B; 5D).   





















































   



























































   

















































































   






























































   

































Figure 3-4:  Overexpression of LKB1 suppresses MITF expression in G361 melanoma cells and 
A2058 melanoma cells, and LKB1 knockdown increases MITF expression in WM88 melanoma 
cells.  LKB1 (A, B) and MITF (C, D) mRNA expression relative to RPL11 and control vector quantified by 
qRT-PCR in G361 melanoma cells (A, C) and A2058 melanoma cells (B, D) after overexpression of 
control vector or titrated LKB1 (WT) (n=1).  Western blot analysis of LKB1 and MITF protein levels in 
G361 melanoma cells (E) and A2058 melanoma cells (F) after overexpression of control vector or titrated 
LKB1 (WT) (n=1).  LKB1 (G) and MITF (H) mRNA expression relative to RPL11 relative and control 
vector quantified by qRT-PCR in G361 melanoma cells after overexpression of control vector or titrated 
kinase defective LKB1 (D194A) (n=1).  (I)  Western blot analysis of LKB1 and MITF protein levels in 
SKMEL5 melanoma cells, UACC62 melanoma cells, and SKMEL90 melanoma cells expressing LKB1 
(WT), kinase defective LKB1 (D194A), or control vector (n=1).  LKB1 (J) and MITF (K) mRNA expression 
quantified by qRT-PCR in WM88 melanoma cells after transfection with control si-Scramble or siLKB1 
(n=3; mean ± SEM).   (L) Western blot analysis of SIK2 and MITF protein levels in MeWo melanoma 
cells expressing wildtype SIK2 (WT), kinase defective SIK2 (K49M), or control vector (n=1).   **P < 0.01, 



































































   






























































   

















Figure 3-5:  A salt-inducible kinase inhibitor rescues MITF expression after LKB1 
overexpression in LKB1-null melanoma cells.  LKB1 (A, B) and MITF (C, D) mRNA expression 
relative to RPL11 and vehicle control vector (n=3, mean ± SEM), and LKB1 and MITF protein level 
(n=1) (E) in G361 melanoma cells (A, C, E) and A2058 melanoma cells (B, D) after infection with 
control or LKB1 (WT) overexpression vector +/- salt-inducible kinase inhibitor (SIKi) HG 9-91-01 or 
vehicle dimethyl sulfoxide (DMSO).  Statistical significance is reported as follows:  *P < 0.05, **P < 
0.01, ***P < 0.001, one-way ANOVA with Dunnett’s multiple comparisons test comparing each 
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LKB1 and SIK effect melanoma proliferation and melanocyte factor 
independent growth, respectively.  
Our results illustrate that LKB1 represses a known oncogene, MITF, through SIK, 
we hypothesized that LKB1 can regulate tumor cell growth through regulation of 
MITF.  We next looked at percent change of cell viability after LKB1 
overexpression using CellTiter-Glo® Cell Viability Assay.  Wildtype-LKB1 (WT) 
overexpression suppresses cell proliferation in G361 melanoma cells (Figure 
6A). Kinase defective LKB1 (D194A) overexpression increased cell proliferation 
in G361 melanoma cells, which may be due to dominant-negative action against 
LKB1 expressed endogenously (Figure 6A).  Furthermore, normal human 
melanocytes require 10% fetal bovine serum, 50ng/mL 12-O-tetradecanoyl 
phorbol-13-acetate, 1 x 10-4 M 3-isobutyl-1-methyl xanthine, 1 µM Na3VO4, 1 x 
10−3 M N6,2’-O-dibutyryladenosine 3:5-cyclic monophosphate for growth in 
culture, and SIK inhibition by HG 9-91-01 treatment of normal human 
melanocytes enhanced factor independent growth (Figure 6B). 






































































Figure 3-6:  Regulation of cell viability by LKB1 and SIK.  (A) Cell viability as measured by CellTiter-
Glo over 7 days of G361 melanoma cells infected with control vector, or titrated LKB1 (WT) or LKB1 
(D194A) overexpression vector. Data shown as percentage of day 1 luminescence (n=1). (B)  Cell 
viability of normal human melanocytes in factor-free media as measured by CellTiter-Glo after 3 days of 
treatment with titrated dose of SIK inhibitor HG 9-91-01 (SIKi) or vehicle (30% propylene glycol + 70% 
ethanol).  Data shown as a percentage of vehicle control luminescence (n=4 mean ± SEM).  For graphs 
in B, statistical significance is reported as follows:  *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 
one-way ANOVA with Dunnett’s multiple comparisons test comparing each time point to vehicle 
treatment.
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Inhibition of SIK1, SIK2, and SIK3 rescues MITF expression in BRAF 
(V600E) transformed immortalized melanocytes 
After 24 hours of incubation in factor free media, normal human melanocytes 
were infected by lentivirus containing control vector or activated NRAS (Q61R) 
vector.  NRAS (Q61R) expression suppressed MITF mRNA expression (Figure 
7).  Furthermore, short hairpin RNA (shRNA) mediated SIK1, SIK2, and SIK3 
knockdown rescued MITF mRNA expression and partial rescue of MITF mRNA 
expression was observed with SIK1 knockdown alone but no effect was 
observed with SIK2 or SIK3 knockdown (Figure 7).   









































Figure 3-7:  Knockdown of SIK rescues MITF in NRAS (Q61R) melanocytes.  Normal human 
melanocytes were infected with shControl vector, NRAS (Q61R), shSIK1, shSIK2, and/or shSIK3 
and incubated overnight in factor-free media.  MITF  mRNA expression relative to RPL11 and 
shControl quantified by qRT-PCR (n=3; mean ± SEM). Statistical significance is reported as 
follows:  **P < 0.01, ****P < 0.0001, one-way ANOVA with Dunnett’s multiple comparisons test 
compared to shControl or shControl + NRAS (Q61R).  (Figure was contributed by Ryo Murakami)
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DISCUSSION 
MITF plays a critical role in oncogenic transformation of BRAF (V600E) 
melanocytes [2], and confers resistance to BRAF and MEK inhibitors in 
melanoma [187, 226, 227].  Yet, MITF is amplified in only 10%-20% of 
melanomas [2, 225].  Our results suggest that LKB1 induction of SIK inhibits 
MITF induction through inhibition of CRTC nuclear localization demonstrating 
how alterations in these upstream regulators of MITF expression could possibly 
rescue MITF in melanomas without genomic alterations in the MITF gene.  
Previously Garraway et al demonstrated that immortalized melanocytes 
expressing BRAF (V600E) or MITF alone are incompatible with growth in factor 
free media, but concurrent expression of both genes allows survival without 
factors, a sign for malignant transformation [2], yet our results show that SIK 
inhibition alone of normal human melanocytes confers factor independent 
growth.  This may be explained by the possible anti-proliferative effects of high 
MITF expression [200], that may be abated with concurrent BRAF (V600E) 
expression.  On the other hand loss of SIK activity may allow for an increase in 
MITF expression that is at the critical level needed for growth factor independent 
survival.  This discrepancy may also be attributed to the differences in 
immortalized melanocytes versus normal human melanocytes used for each 
experiment or off-target effects of the SIK inhibitor.  We also showed that 
knockdown of SIK1, SIK2, and SIK3 in NRAS (Q61R) expressing melanocytes 
rescues MITF expression.  Therefore, alterations in this pathway may contribute 
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to melanoma formation and also resistance to MAPK kinase inhibitors by 
enhancing MITF expression.   
Unlike SIK knockdown, LKB1 knockdown in NRAS (Q61R) expressing 
melanocytes did not rescue MITF expression (data not shown).  Previously it was 
shown that BrafV600E melanocytes are growth arrested in mice due to oncogene-
induced senescence [241].  When these BrafV600E melanocytic nevi lose LKB1 
there is an increase in melanocyte proliferation yet no melanoma progression 
[241].  This may be due to LKB1’s role as a master kinase regulator of AMPK 
and AMPK-related kinases [237] allowing it to modulate tumors both as a tumor 
suppressor and offer advantages for tumor survival reflected by existence of both 
low and high LKB1 malignant tumors [242]. Here we show that in human BRAF 
(V600E) mutated G361 melanoma cells, LKB1 suppresses MITF induction and 
cell proliferation, an effect previously attributed to G1 cell cycle arrest [357].  
MITF can regulate G1 cell cycle progression through cyclin-dependent kinase 2 
(Cdk2) [217, 358], hinting at a possible link between MITF upregulation and 
LKB1 induced cell arrest, but LKB1 can work through other mechanisms to 
regulate G1-S transition [276].  Subsequent analysis of tumorigenic potential of 
LKB1 rescued G361 melanoma cells and it’s reliance on MITF expression is still 
needed.  Although loss of LKB1 may not be the only step needed for melanoma 
formation in MAP kinase pathway mutated melanocytes, this loss may still be 
critical for initiating or maintaining tumor state, and further investigation is needed 
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to evaluate tumorigenic potential of BRAF (V600E) and also NRAS (Q61R) 
melanoma cells with rescue of LKB1.   
Overall, our findings establish SIK and LKB1 as negative regulators of the CRTC-
CREB-MITF pathway, an axis altered in almost half of TCGA skin cutaneous 
melanoma samples, and demonstrate how this pathway could potentially play a 
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Microphthalmia associated transcription factor (MITF) is the master regulator of 
pigment-related genes and melanocyte differentiation [161, 162]. α-MSH, 
released by keratinocytes in response to UV-induced DNA damage, binds to and 
activates the melanocortin 1 receptor 1 (MC1R) on melanocytes initiating a 
signaling cascade that results in cyclic AMP-responsive element binding protein 
(CREB) activation, MITF induction and dark-pigment eumelanin production [1, 
148, 149].  Eumelanin protects against UV-induced DNA damage [359].  
Additionally, eumelanin plays a role in hair color determination.   Physiologic hair 
pigmentation is dependent on both the quantity and the ratio of eumelanin and 
red-pigment pheomelanin [360].  Interestingly, in some melanoma cells, 
upregulation of MITF decreases cell proliferation. [200].  Therefore, there are a 
variety of potential applications for which a pharmacological inducer of MITF can 
be used including increasing eumelanogenesis for sun protection and hair 
darkening, and as a melanoma therapeutic. 
Independent of MC1R activation, cAMP-regulated transcriptional co-activator 
(CRTC) binding to CREB induces MITF expression [238], and salt-inducible 
kinase 2 (SIK2) regulates MITF expression and melanogenic programming 
through inhibition of CRTC nuclear translocation [238, 361].  Furthermore, small 
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molecule SIK inhibitors upregulate MITF and induce melanogenesis in vitro and 
when topically applied induced pigmentation in Mc1r-deficient mice and normal 
human skin (Chapter 2). Hence, we hypothesized that small molecule inhibitors 
of SIK could be used to protect against UV-induced DNA damage, stimulate dark 
















Materials and Methods 
Materials. Salt inducible kinase inhibitors, HG 9-91-01 and HG 11-139-02 were 
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dissolved in 30% propylene glycol (Sigma-Aldrich) + 70% 200 proof ethanol 
(Decon Laboratories Inc).  
Citrate phosphate buffer (pH 5.0):  5.10 g citric acid monohydrate, 7.30 g 
Na2HPO4, 1000 mL of distilled water. 
Substrate solution:  8 mg o-Phenylene diamine, 4 µL H2O2 (35%), 20 mL of 
citrate-phosphate buffer (pH 5.0). 
 
Cell Culture.  Human melanoma cells were grown in either RPMI or DMEM 
medium + 1% penicillin/streptomycin/glutamine + 5% fetal bovine serum.  
 
Human Tissue Samples. Skin samples considered surgical waste were 
obtained de-identified from healthy donors undergoing reconstructive surgery 
according to institutional regulation. 
 
Human skin experiments.  Full thickness human breast skin explants were 
cultured in petri dishes with a solid phase and liquid phase phenol red free 
DMEM medium with 20% penicillin/streptomycin/glutamine, 5% fungizone 
(Gibco), and 10% fetal bovine serum.  Explants were treated daily with vehicle or 
SIK inhibitor as indicated in figure legend.   Skin was cleaned with PBS and skin 
darkening was measured using a colorimeter.  Skin was then treated with no UV, 
150 mJ/cm2  of UVB, or 50 mJ/cm2 of UVB.  After UV treatment, DNA was 
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extracted and cyclobutane pyrimidine dimer ELISA was performed to detect DNA 
damage.   
 
Colorimeter Measurements. Differences in darkening of the skin were 
measured by reflective colorimetry (Commission Internationale de l’Eclairage 
[CIE] L* white-black color axis) utilizing a CR-400 Colorimeter (Minolta) calibrated 
by a calibration plate (C: Y 93.1, x .3133, y .3194) before each set of 
measurements.    
 
DNA extraction.  DNA was extracted using DNeasy Blood and Tissue Kits 
(Qiagen) according to protocol for tissue samples supplied by manufacturer. 
 
Cyclobutane pyrimidine dimer detection.  Polyvinylchloride flat-bottom 96-well 
microtiter plates (Thermo Scientific) were coated with 50 µL/well of 0.003% 
protamine sulfate solution and dried overnight in a 37oC oven.  Plates were 
washed the next day with 100 µL/well of distilled water.  Skin sample DNA 
concentrations were measured using a Nanodrop 1000 (Thermo Scientific).  All 
DNA samples were normalized to a final concentration of 0.4 ng/µL.  DNA 
samples were sonicated at high speed for 5 minutes and then placed in a 100oC 
heat block for 10 minutes and chilled on ice immediately after for 15 minutes.  50 
µL of DNA sample was added to each well of the 0.003% protamine sulfate 
coated 96-well plate and plates were dried in a 37oC oven for at least 30 minutes 
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or till plate was completely dry.  Plates were washed 5 times with 1x PBS-T 
(phosphate buffered saline plus tween 20).  Plates were blocked with 150 µL/well 
of 2% FBS (fetal bovine serum) in PBS and incubated in a 37oC incubator for 30 
minutes.  Liquid was aspirated and plates were washed 5 times with 150 µL/well 
of PBS-T.  150 µL/well of mouse anti-cyclobutane pyrimidine dimers 
[Clone:TDM2] (Cosmo Bio) was added and plates were incubated in a 37oC 
incubator for 30 minutes.  Liquid was aspirated and plates were washed 5 times 
with 150 µL/well of PBS-T.  150 µL/well of Biotin-XX F(ab’)2 fragment of goat anti-
mouse IgG (Invitrogen) was added and plates were incubated in a 37oC 
incubator for 30 minutes.  Liquid was aspirated and plates were washed 5 times 
with 150 µL/well of PBS-T.  150 µL/well of streptavidin horseradish peroxidase 
(HRP) conjugate (Invitrogen) was added and plates were incubated in a 37oC 
incubator for 30 minutes.  Liquid was aspirated and plates were washed 5 times 
with 150 µL/well of PBS-T.  150 µL/well of citrate-phosphate buffer was added to 
plates and citrate-phosphate buffer was not removed till substrate solution was 
ready.  Substrate solution was made fresh, and citrate-phosphate buffer was 
aspirated and 100 µL/well of substrate solution was added.  Plates were 
incubated in a 37oC incubator for 30 minutes.  Reaction was stopped with 50 
µL/well of 2M H2SO4.  Absorbance at 492 nm of each well was determined by a 
spectrophotometer.   
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Antibodies.  anti-cyclobutane pyrimidine dimers [Clone:TDM2] (1:1000) antibody 
was obtained from Cosmo Bio.  Biotin-XX F(ab’)2 fragment of goat anti-mouse 
IgG (1:2000) and streptavidin horseradish peroxidase (HRP) conjugate (1:5000) 
was obtained from Invitrogen. 
 
Mouse pigmentation experiments.  For in vivo darkening experiment an adult 
MC1Re/e mouse was used. The mouse was waxed and treated with 160 uL of 
vehicle control (30% propylene glycol + 70% ethanol) or 160 uL of 75.0 mM HG 
9-9-01 until uniform gross darkening was visible, as stated in figure legend.   
 
Cell Viability Assay.  Cell viability assay was conducted according to protocol 
supplied by manufacturer for CellTiter-Glo® Cell Viability Assay. 
 
Cell differentiation Experiment.  For cell differentiation experiment, UACC62 
human melanoma cells were treated 1x/day with SIK inhibitor or vehicle control 
(30% propylene glycol + 70% ethanol).  After three days, cells were imaged using 
light microscopy. 
 
Statistical analysis.  Data was analyzed using Prism 6.0 (GraphPad).  Data are 
presented as the mean ± SEM.   
Statistical significance of differences between experimental groups for 
colorimeter readings of human skin and cell viability of melanoma cells were 
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RESULTS 
Topical treatment of human skin with small molecule SIK inhibitors 
reduces DNA damage. 
Since topical SIK inhibitor treatment of human skin explants induced 
pigmentation (Chapter 2), we wanted to test if this pigmentation afforded by SIK 
inhibitor treatment protected against UV-induced DNA damage.  6 days of 
treatment (1x/day) of human skin explants with topical application of SIK 
inhibitors HG 9-91-01 and HG 11-139-02 induced significant darkening as 
determined by reflective colorimetry analysis (Commission Internationale de 
l’Eclairage [CIE] L* white-black color axis [340] (Figure 1A).  Furthermore, 
treatment with SIK inhibitors protected against cyclobutane pyrimidine formation 
after 150 mJ/cm2 or 50 mJ/cm2 UVB (Figure 1B).   





Figure 4-1:  SIK inhbitors protect against cyclobutane pyrimidine dimer formation.  (A) Reflective 
colorimetry measurements (L* white-black color axis) of human breast skin explants treated with topical 
application of vehicle control (70% ethanol; 30% propylene glycol) or 75 mM SIK inhibitor HG 9-91-01 or 
HG 11-139-02 for 6 days (30 µL; 1x/day)  (n=4, mean ± SEM).  (B) Cyclobutane pyrimidine dimers  in 
normal human breast skin treated as described in A with and without 50 mJ/cm2 or 150 mJ/cm2 UVB 
treatment measured by ELISA.  Data shown as relative to control samples with no UV treatment (n=1). 
For graph in A statistical significance is reported as follows:  ****P < 0.0001, one-way ANOVA with 
Dunnett’s multiple comparisons test comparing each treatment to vehicle control.
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SIK inhibitor induces darkening in mice with inactive melanocortin 1 
receptor and only dermal melanocytes. 
Topical SIK inhibitor treatment can rescue melanogenesis epidermal 
melanocytes of mice with inactivating Mc1re/e mutant allele and a transgene, 
K14-SCF, in which Stem Cell Factor expression is driven by the Keratin-14 
promoter, allowing for epidermal homing of melanocytes [1, 339] (Chapter 2).  
We tested to see if a higher dose than that previously used for epidermal 
pigmentation of topically applied SIK inhibitor could induce pigmentation in 
Mc1re/e mice lacking K14-SCF with melanocytes confined to dermal hair follicles.  
Topical 75 mM SIK inhibitor treatment of an Mc1re/e mouse induced darkening 
only in treated areas (Figure 2). 











Figure 4-2:  Topical treatment with HG9-91-01 causes darkening in a MC1Re/e mouse. MC1Re/e 
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SIK inhibition leads to growth inhibition of melanoma cells. 
Since it was previously established that SIK inhibitors could induce MITF in vitro 
(Chapter 2), and MITF decreased proliferation of some melanoma cells [200], we 
wanted to test the effect of SIK inhibitor treatment on melanoma proliferation.  
SIK inhibitor treatment of SKMEL-5 melanoma cells,  SKMEL-30 melanoma cells, 
WM115 melanoma cells, A375 melanoma cells, and UACC62 melanoma cells 
reduced cell proliferation (Figure 3A-3E). Furthermore, SIK inhibitor treatment of 
UACC62 melanoma cells increased dendricity a sign of melanocyte-lineage cell 
differentiation (Figure 3F).  








































































































































Figure 4-3:  Inhibition of SIK in melanoma cells decreases cell proliferation.   Cell viability of SKMEL5 
melanoma cells (A), SKMEL30 melanoma cells (B), WM115 melanoma cells (C), A375 melanoma cells (D), 
and UACC62 melanoma cells (E) measured by CellTiter-Glo after 3 days of treatment with titrated dose of 
SIK inhibitor HG 9-91-01 (SIKi) or vehicle (30% propylene glycol + 70% ethanol).  Data shown as a 
percentage of vehicle control luminescence (n=4 mean ± SEM).  (F) Bright field image of UACC62 
melanoma cells after 3 days of treatment with vehicle control (30% propylene glycol + 70% ethanol) or SIK 
inhibitor HG 9-91-01 (SIKi) (400x magnification) (n=1) ( (statistical significance is reported as follows:  *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA with Dunnett’s multiple comparisons test 
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DISCUSSION  
The causal association between ultraviolet (UV) light and the most prevalent 
forms of skin cancer (basal cell carcinoma, squamous cell carcinoma, and 
melanoma) is well established [18-20, 139], and many driver gene mutations for 
all three skin cancers are UV-induced mutations [34, 37, 39, 113].   DNA 
cyclobutane pyrimidine dimers, which are caused by UV damage, are the 
initiating lesions responsible for a large number of mutations induced by UV [148, 
362].  Our results demonstrate that topical application of SIK inhibitors to human 
skin protects against cyclobutane pyrimidine dimer formation after UV exposure 
supporting the therapeutic use of topical inhibitors as a primary strategy for skin 
cancer prevention.   
Furthermore our results suggest that topical SIK inhibitor treatment can also 
induce hair darkening conceivably demonstrating an alternative method for hair 
darkening than hair dyes, which are widely used [363].  Furthermore, some black 
color hair dyes contain cytotoxic and genotoxic elements, which can be 
mutagenic [364].  We believe with higher doses, as used here, topical application 
can allow for dermal penetration of SIK inhibitors.  Further confirmation is needed 
for if the darkening observed is within the hair shaft or restricted to the dermal 
bulb where dermal melanocytes reside.  
Furthermore, SIK inhibitor treatment of melanoma cells decreased proliferation 
and also increased melanoma dendricity, an indicator of melanocyte lineage cell 
differentiation.  A similar growth inhibitory effect has been previously seen with 
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forskolin treatment of melanoma cells, and this effect was dependent on MITF 
expression [200].  Further investigation is still needed to see if this effect is 
dependent or independent of MITF.  Our data demonstrate that SIK inhibitors, 
possibly through regulation of MITF expression, have a wide range of therapeutic 


















	  	   	  
111	  
Chapter 5 Discussion 
SIK Inhibitors: Implications for Skin Cancer Prevention 
Alternative solutions for photoprotection are needed for individuals who are 
incapable of sun-protective eumelanin production. With the rising incidences of 
skin cancers and the dangers associated with common cultural practices to 
induce tanning, such as ultraviolet tanning devices, there is a need for the 
identification of safer methods for activation of the tanning pathway [9, 333, 334, 
365].  
Topical sunscreens prevent DNA damage in human skin [366], and previous 
studies show that regular use of synthetic photoprotection products such as 
sunscreen reduces the risk of developing melanoma [367].  Sunscreens should 
be reapplied every 2 hours and losses effectiveness if stored at temperatures 
above 25oC, yet knowledge of these details is lacking in many adults [368].  
Furthermore reapplication contributes to inconvenience of sunscreen use.  Not 
only this, many sunscreens do not filter for visible and infrared spectral regions, 
which contribute to free radicals production in human skin [369].  Additionally, 
other methods of sun protection such as cotton fibers with UV protective coating 
[370] offer alternatives to sunscreen but remain inconvenient in warm weather 
environments.  Even though many patients are aware of the risk of UV induced 
skin cancer and skin aging, sun avoidance and sun protective techniques are not 
utilized by many people [368, 371], which may be due to inconvenience of 
currently available methods, desire for tanned skin, and “addiction” to UV through 
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recently identified β-endorphin dependent mechanisms [372].  While inhibition of 
the SIK pathway with flavonoids has demonstrated to increase melanogenesis 
via an MC1R independent induction of MITF  in mice, the ability of these 
molecules to induce  human skin tanning has not been demonstrated [361].   
Our findings demonstrate that topical small molecule SIK inhibitors induce 
pigmentation production in human skin that mimics normal tanning.   This 
increase in melanin likely will last the full skin turn-over cycle, normally around 2 
weeks, allowing for a more user-friendly application cycle than sunscreen.  
Furthermore, SIK inhibitors would allow skin darkening for aesthetic reasons 
without the use of harmful tanning beds. Topical application of SIK inhibitors also 
decreased cyclobutane pyrimidine dimer formation in UV irradiated skin, 
demonstrating the protective effects of topical SIK inhibitor application against 
these UVB induced DNA lesions, which have been implicated as the primary 
driver of UV-induced mutations in melanoma and non-melanoma skin [113, 148].  
Therefore, SIK inhibitors may overcome many shortcomings of current methods 
of sun protection and could serve as a new class of photoprotective agents.  
 
 
Targeting the LKB1-SIK-CRTC-MITF Pathway  
Most melanomas require MITF [2], but it is unclear how MITF is upregulated in 
melanoma.  This may be explained by other genomic, transcriptional, post-
transcriptional and epigenetic alterations that can induce MITF upregulation.  Our 
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findings demonstrate that aberrations in the LKB1-SIK-CRTC axis can lead to 
upregulation of MITF.    
Although primary somatic mutations of LKB1 are rare in sporadic cancers [373], 
we found that majority of melanoma cell lines have a partial loss of LKB1 on the 
protein level compared to basal levels in melanocytes.  Not only this, but we 
discovered that multiple melanoma cells have a decrease in SIK2 and/or SIK1.  
Interestingly, SIK1, SIK2, SIK3 knockdown in NRAS (Q61R) overexpressing 
human melanocytes  led to rescue of MITF expression, yet preliminary data 
shows LKB1 knockdown did not recapitulate this effect (data not shown).  This 
may be the result of LKB1’s role as a master kinase regulator in the cell, and with 
decrease in LKB1 activity multiple downstream kinase pathways are altered 
some of which may cancel the effect of CRTC nuclear translocation and 
activation of CREB allowing for MITF levels to remain unaltered.  On the other 
hand, we demonstrate that LKB1 rescue in melanoma cells decreases MITF 
expression in a SIK-dependent manner, indicating that some melanoma cells rely 
on loss of LKB1-SIK to maintain high MITF status.   
While MITF plays a key pro-survival role in melanoma, targeting MITF 
directly faces many challenges including nuclear localization (increasing difficulty 
for drugs to reach their targets), homology among other transcription factors in 
the same family (increasing the need for highly specific drugs), and larger 
surface areas for binding targets with no binding pocket for drugs, and till date no 
direct inhibitor of MITF has been developed [374, 375].  This emphasizes the 
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need of identifying pathways and developing therapies targeting upstream 
modulators of MITF expression. An in vivo systemically well-tolerated CREB 
inhibitor is efficacious against human breast cancer cells and tumor growth [376, 
377], and could potentially offer a new therapeutic strategy for targeting high 
MITF melanomas, but no drug targeting CRTC binding to CREB has been 
developed. As LKB1-SIK seems to play a role in driving CREB-dependent MITF 
expression in many melanomas, it could serve as a potential therapeutic target.    
However, targeting tumor suppressors such as LKB1 and SIK for cancer therapy 
also demonstrate challenges.  One method to replace an absent or 
nonfunctioning protein is gene therapy, a method of introducing foreign DNA into 
a cell utilizing a viral vector delivery system [378].  There are some technical 
challenges with this therapy when targeting tumors including the efficiency of the 
virus vector to reach the tumor cells and the potential harm to normal cell 
function [378].  Currently, in the United States gene therapy is only available in 
the research setting, yet clinical trials are underway, but the European Medicines 
Agency has approved an adeno-associated virus vector expressing lipoprotein 
lipase in 2012 [379].  As technology and medicine progress gene therapy may be 
a feasible option for cancer therapy in the future. 
We also demonstrate that inhibiting SIK induces melanoma growth suppression, 
which might be another possible therapeutic avenue for targeting melanomas 
through this pathway.  Further investigation is still needed to determine if this 
anti-proliferative effect of SIK inhibitor treatment is dependent on MITF 
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upregulation, but a previous study demonstrated that high MITF levels induced 
by forskolin have anti-proliferative effects on melanoma cells [200].  Furthermore, 
a more differentiated state and MITF are also linked to cell cycle arrest, which 
may be due to MITF induction of INK4A [222].  Our results also hint at the 
possibility of targeting the SIK pathway to induce MITF in melanomas as a way to 
inhibit tumor progression. 
 
Future Directions 
Our study demonstrated that the LKB1/SIK axis negatively regulates MITF 
expression and use of topical small molecule SIK inhibitors induces MITF and 
pigment production.  A next step to this project is to further elucidate the 
mechanism of action through which SIK and SIK inhibitors regulate MITF 
transcription.  SIK isoforms phosphorylate and regulate nuclear translocation of 
both CRTC2 and class II HDAC [380].  Previously, SIK2’s inhibition of CRTC2 
nuclear translocation decreases MITF gene expression and melanogenic 
programming [238]. Moreover, SIK inhibitors increase nuclear translocation of 
class II HDACs ( HDAC4/5) and HDAC inhibitors suppress MITF expression in 
melanocytes [381].  We hypothesize that small molecule SIK inhibitors work 
through both increasing CRTC and class II HDAC nuclear translocation, which 
subsequently upregulate MITF expression.  To test this, we propose to utilize 
immunocytochemistry to visualize nuclear and cytoplasmic localization of CRTC 
isoforms and class II HDACs after SIK isoform overexpression, SIK knockdown, 
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and SIK inhibitor treatment of cells.   Overexpression of a dominant negative 
CRTC isoforms or small interfering RNAs targeting class II HDAC with concurrent 
SIK inhibitor treatment or SIK isoform(s) knockdown will also be performed to 
examine if SIK inhibitor induction of MITF expression is dependent on CRTC or 
HDAC.  Furthermore, CRTC2 transcriptional regulatory activity is dependent on 
nuclear localization and phosphorylation of CRTC2 by SIK at serine 171 or serine 
307 prevents nuclear translocation [382].  To see if LKB1/SIK suppression of 
MITF induction is dependent on SIK phosphorylation of CRTC2, we propose to 
overexpress CRTC2 mutated in the SIK phosphorylation site, CRTC2 (S171A) or 
mutated at Serine 307 [382]. 
Moreover, additional proteins within this pathway may be the regulators of MITF.  
Other downstream LKB1 activated kinases, such as MARK and AMPK, 
phosphorylate CRTC2 and sequester it in the cytoplasm, and these proteins 
should also be investigated [382].  Additional investigation is also needed to 
elucidate the effects of aberrant expression or function of these tumor 
suppressors on melanoma formation and proliferation.   
Additionally, our results demonstrates a darkening phenotype in MC1Re/e without 
the melanocyte epidermal homing gene K14-SCF [339] allowing for nongenotoxic 
pigment production unlike the genotoxicty observed for some hair dyes [364].  
Further investigation is needed on if this phenotype is due to increase pigment in 
the hair shaft or through darkening of the dermal region around hair follicle 
melanocytes.  Histological analysis and inspection of hair after SIK inhibitor 
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treatment can further elucidate the cause of the darkening phenotype observed.  
Also, further exploration of topical SIK inhibitor treatment effects on human hair 
darkening is needed. 
Furthermore, another future focus of this study will be to ascertain the safety of 
SIK inhibitor treatment with regards to melanoma formation due to the SIK 
inhibitors positive regulation on MITF expression.  While SIK induced 
pigmentation offers protection against UV induced DNA damage, preventing 
some of the initiating factors for melanoma, it does this by activating the MITF 
axis which could be important for induction and survival of melanoma cells, for 
example in a nevus cell with BRAF (V600E) mutation induction of MITF may help 
transformation to cancer.  To investigate this further, we propose to treat a 
BRAFV600E inducible mouse model with tamoxifen-mediated activation of Cre 
recombinase (Tyr-Cre(ER)T2 ) currently available in our lab with topical SIK 
inhibitor once BRAFV600E is induced.  After treatment with SIK inhibitor, mice will 
be treated with UV irradiation or mock UV and presence of skin cancers will be 
monitored.  We hypothesize that topical treatment with SIK inhibitors will not lead 
to an increase in tumor formation and will be protective against skin cancer 
formation.  With regards to keratinocyte lineage tumors, eumelanin is protective 
against tumor formation [20].  Furthermore, evidence also shows that dark 
pigment may be protective against ultraviolet-radiation dependent and 
independent melanoma formation [20, 383].  In the Garraway study 
demonstrating MITF as an oncogene needed for melanocyte transformation into 
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melanoma they utilized immortalized melanocytes with p53 inactivation and 
constitutively active CDK4(R24C) (incapable of p16INK4A binding) and hTERT 
expression [2, 384], which is not reflective of physiologically normal melanocytes.  
p53 mutations in melanoma can be due to UVB and UVA induced signature 
mutations C > T and G >T, respectively [113].  Furthermore, the upstream 
regulator of CDK4, p16INK4A , is lost in 90% of metastatic melanomas and 
mutation of p16INK4A can also be UV-induced [113, 385].  These mutations may 
be needed for melanoma formation in melanocytes with BRAF(V600E) and we 
predict eumelanin induced by topical SIK inhibitor treatment will be protective 
against UV radiation and formation of these mutations.  Furthermore, SIK 
inhibitors transiently turn on MITF expression constitutively upregulated MITF 
observed in high MITF melanomas. 
To further investigate if SIK inhibition promotes tumorigenic programming in vitro 
and if this programming is dependent on MITF, BRAF(V600E) expressing 
melanocytes with SIK knockdown (BRAFV600E/SIK-) with and without knockdown 
to basal MITF levels (BRAFV600E/SIK-/MITF-) will be grown utilizing the soft agar 
assay, an in vitro assay testing anchorage-independent growth, a characteristic 
of tumor cells.  If cells form colonies on soft agar, cells will be xenografted in 
immunodeficient mice to determine if this effect is recapitulated in vivo.  
Furthermore, rescue of LKB1 and SIK isoforms in multiple melanoma cells 
deficient of the kinases will be performed and cell proliferation will be monitored, 
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and xenografts of these cells will allow us to investigate the effects of rescue on 
tumor growth, proliferation, and metastatic potential.   
On the other hand, our results also demonstrate that SIK inhibitor treatment of 
some melanoma cells inhibits cell proliferation.  Further investigation is needed 
on if this inhibitory effect is dependent on MITF induction or an off-target effect of 
the drug.  To elucidate if the mechanism of inhibition is dependent on MITF, cell 
growth of melanoma cells will be monitored after knockdown of MITF with 
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